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An association between type 2 diabetes (T2DM) and depression has 
been reported in epidemiological studies.  The mechanisms underlying the 
T2DM-depression link remain unclear.  One possible question is whether 
the co-occurrence of T2DM and depression is due to common genetic and/or 
common environmental vulnerabilities. A genetic overlap between T2DM 
and depression will provide evidence supporting a common biological 
pathway to both disorders. 
Method 
This thesis applied three methodological approaches: i) structural 
equation modelling of twin data, ii) polygenic score analysis and iii) linkage 
disequilibrium score regression using genome-wide association studies 
(GWAS) data.  For the first approach, the primary dataset was the Swedish 
Twin Registry with replication in the Danish Twin Registry and Colombo 
Twin and Singleton Study (COTASS-2).  For the second and third 
approach, the population cohorts deCODE and UK Biobank, and the 
Psychiatric Genomics Consortium Major Depressive Disorder (PGC-MDD-
29) dataset were used.   
Result 
In the twin studies, a genetic overlap between T2DM and depression 
was observed in the Swedish Twin Registry and the finding was replicated 
in the Danish Twin Registry and COTASS-2.  In the GWAS datasets, 
T2DM-polygenic scores were not a major contribution to depression nor 
depression-polygenic scores for T2DM in both deCODE and UK Biobank.  
A small, negative but statistically significant association was observed 
 between feelings of guilt/worthlessness and T2DM-polygenic scores in the 
PGC-MDD-29 dataset.   
Conclusion 
Twin studies have suggested a genetic overlap between T2DM and 
depression.  There are many reasons to explain the discrepancies in 
findings between twin studies and GWAS.  Clarifying the shared 
heritability between these two complex traits is an important next step 
while gene-environment interaction is an area that needs to be explored, 
given genotypes can affect an individual’s responses to the environment 
and environment can differentially affect genotypes expression.  
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“Heaven knows we need never be ashamed of our tears, for they are rain 
upon the blinding dust of earth, overlying our hard hearts. I was better after 
I had cried, than before - more sorry, more aware of my own ingratitude, 
more gentle.”  




Type 2 diabetes (T2DM) and depression are both common disorders 
with a lifetime prevalence of 8.3% and 16% respectively (International 
Diabetes Federation, 2012; Kessler et al., 2003).  In the UK, T2DM affects 
7% of the population while depression affects 20% (Holman, Forouhi, 
Goyder, & Wild, 2011; Office for National Statistics, 2016). They were 
respectively ranked as the seventh and second leading causes of disability 
adjusted life years in a global burden of disease study conducted in 2013 
(Global Burden of Disease Study Collaborators, 2015).  The associated 
costs to the National Health Service is staggering, with one study 
estimating the direct cost to be £8.8 billion for T2DM in 2010, and £1.7 
billion for depression in England in 2007 (Hex, Bartlett, Wright, Taylor, & 
Varley, 2012; McCrone, 2008).  The respective figures are projected to be 
£15.1 billion by 2035 and £3 billion by 2026 (Hex et al., 2012; McCrone, 
2008).   
1.2 What is T2DM?  
T2DM is a chronic medical disorder occurring when there is an 
ineffective use of insulin produced by the body, and/or a progressive 
reduction in insulin production.  The number of people with diabetes 
worldwide has increased from 108 million in 1980 to over 400 million in 
2014, with a global prevalence (age-standardized) rising from 4.7% in 1980 
to 8.5% in 2014 among adults (NCD Risk Factor Collaboration, 2016). 
Prevalence rates during this period has either increased or at best 
remained unchanged in every country, with the rise being most noticeable 
in middle- and low-income countries (Mathers & Loncar, 2006). The largest 
numbers of people with diabetes were estimated for the South-East Asia 
and Western Pacific Regions, and tighter they account for approximately 
half of the diabetes cases in the world. 
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Risk factors for T2DM include obesity, hypertension, 
hyperlipidaemia, poor dietary habits and physical inactivity. The 
prevalence of T2DM has increased secondary to the obesity epidemic 
(Holman et al., 2011).  One of the consequences of poorly uncontrolled 
diabetes is raised blood glucose level (hyperglycaemia).  This can lead to 
long-term macrovascular and microvascular complications such as an 
increased risk of myocardial infarction, ischaemic stroke, retinopathy and 
neuropathy.  
Achieving and maintaining optimal glycaemic control is therefore 
essential for individuals with T2DM. A review of 26 general practices in 
South London reported the median proportion of diabetic patients with a 
HbA1c (a measure of glycated haemoglobin which is indicative of average 
blood glucose levels over 3 previous months) of ≤57.4 mmol/mol was 59.0% 
(Gulliford, Ashworth, Robotham, & Mohiddin, 2007; Mattila & de Boer, 
2010). Diabetes management is, however, complex as optimising glycaemic 
control is only one aspect of care.  Timely prevention, detection and 
management of complications are equally important in improving the 
quality of life for an individual.  The latest recommendations from the 
National Institute for Health and Care Excellence (NICE) include patient 
education, dietary advice, blood pressure management and drug treatment 
(Gatineau et al., 2014; McGuire, Longson, Adler, Farmer, & Lewin, 2016).  
They also emphasise the importance of involving and supporting patients 
in decisions about their individual blood glucose target.  NICE 
recommends individuals with T2DM should receive annual health checks 
to monitor and manage their condition, in order to reduce risks of diabetes-
related complications.   
1.3 What is depression?  
According to the fifth edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM), the core symptoms of depression 
include low mood and anhedonia (loss of interest in activities once enjoyed) 
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(American Psychiatric Association, 2013).  It can lead to various 
psychological and physical difficulties, such as loss of appetite, insomnia, 
fatigue, poor concentration, feelings of guilt/worthless and suicidality. 
Depression can also have significant impacts on an individual’s ability to 
function at work and at home.  The severity of depression is determined by 
the number, nature and severity of symptoms, as well as their effects on 
functional impairment.  Symptoms must be present for at least two weeks 
for a diagnosis of depression.   
There are wide variabilities in prevalence estimates for depression 
across the world.  The first cross-national study was conducted in the early 
1990s.  It reported lifetime prevalence estimates of depression ranging 
from 1.5% (Taiwan) to 19.0% (Beirut), and twelve-month prevalence 
estimates ranging from 0.8% (Taiwan) to 5.8% (Christchurch, New 
Zealand) (Weissman et al., 1996) .  A subsequent comparison in the early 
2000s reported lifetime prevalence estimates of depression from 1.0% 
(Czech Republic) to 16.9% (USA), and twelve-month prevalence estimates 
ranging from 0.3% (Czech Republic) to 10% (USA) (Andrade et al., 2003). 
The cross-national differences observed has been attributed to be due to a 
combination of definition of depression, instruments used and study design 
factors (Kessler & Bromet, 2013). 
Depression remains a common psychiatric disorder worldwide, with 
the World Health Organisation currently ranking it as the fourth leading 
cause of disability worldwide (Murray & Lopez, 1996a) and projecting it as 
the second leading cause by 2020, it will be the second leading cause 
(Murray & Lopez, 1996b). It is usually first presents in primary care 
settings (Goldberg & Huxley, 1980).  Depression is, however, often 
undetected and untreated, resulting in considerable service and societal 
costs.  The first onset of depression is during the mid-20s, with a female 
predominance (Seedat et al., 2009).    
Risk factors for depression include genetic and environmental 
factors, such as socioeconomic status, childhood adversities and experience 
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of recent negative life events (Otte et al., 2016).  The clinical course of 
depression is often chronic, or remitting and relapsing, with residual 
symptoms and functional impairment being present between episodes. The 
key goal of treatment is complete remission (the absence of disease), as this 
is associated with a reduced likelihood of relapse.  The main modality of 
treatment for depression is psychopharmacology and psychotherapy, with 
most guidelines recommending a combination of medication and 
psychotherapy for individuals with severe depression (National Institute 
for Health and Care Excellence (2016).  A substantial number of patients 
may still remain unwell after several treatment attempts (Rush et al., 
2006). 
The lack of clinical effectiveness observed with treatment for 
depression, in addition to having no established biomarker in the daily 
clinical setting, could reflect in part the heterogeneous nature of 
depression (Kunugi, Hori, & Ogawa, 2015).  This is further complicated by 
the number of depressive symptoms being included in the DSM.  For 
example, 227 or more different symptom combinations are possible for an 
individual to meet DSM-IV or DSM-5 diagnostic criteria for depression 
(Galatzer-Levy & Bryant, 2013).  Substantial heterogeneity is therefore 
observed in depression from symptom clusters, clinical course to response 
to pharmacological treatment (Ghaemi & Vohringer, 2011). It has been 
suggested specific depression subtypes are associated with different 
biological correlates (Lamers et al., 2013).  Adopting a categorical 
classification based solely on phenomenology might hinder a more 
comprehensive understanding of its complex pathophysiology.   
1.4 What is the T2DM and depression 
association? 
Both cross-sectional and longitudinal studies have reported 
bidirectional association between T2DM and depression (Chen, Chan, 
Chen, Ko, & Li, 2013; Golden et al., 2008), with up to a 60% increased risk 
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for developing T2DM in individuals with depression; and in the reverse 
direction, 15% for incidental depression in those with T2DM (Mezuk, 
Eaton, Albrecht, & Golden, 2008; Rotella & Mannucci, 2013).  The T2DM-
depression link has been associated with adverse effects on diabetes 
outcomes including suboptimal glycaemic control, greater complications 
and higher rates of mortality.  In addition, an association has been 
observed between depression and all stages of the clinical course of T2DM 
from insulin resistance to mortality (De Groot, Anderson, Freedland, 
Clouse, & Lustman, 2001; Kan et al., 2013; Katon et al., 2005; Lustman et 
al., 2000). 
The underlying pathogenesis of the T2DM and depression 
association is complex and likely to arise from interplay of both genetic and 
environmental factors.  Female sex, low socioeconomic status, social 
isolation, smoking, the presence of diabetes complications, duration of 
diabetes and persistence of poor glycaemic control have all been attributed 
as risk factors for depression specific to diabetes (E., Hermanns, & 
Nouwen, 2010; Leone, Coast, Narayanan, & de Graft Aikins, 2012; Roy, 
Lloyd, Parvin, Mohiuddin, & Rahman, 2012; Shehatah, Rabie, & Al-
Shahry, 2010).  Behavioural and lifestyle factors such as physical 
inactivity and poor self-care have, on the other hand, been implicated as 
mediating factors in elevating the risk of diabetes in individuals with 
depression (Golden et al., 2008).  In addition, obesity, stressful life events, 
perceived burden of chronic illnesses, hypercortisolism and disturbed 
immune functions have been attributed to contribute to the T2DM-
depression association (Kan et al., 2013; Renn, Feliciano, & Segal, 2011). 
A question of interest is whether the association between T2DM and 
depression is predominantly due to shared genetic and/or environmental 
vulnerability.  The evidence for a genetic component to T2DM is well-
established, including observations from twin studies, linkage studies and 
genome-wide association studies (GWAS) (Barroso, 2005; Fuchsberger et 
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al., 2016).  A recent meta-analysis estimates heritability for T2DM to be 
72% (95% confidence interval (95% CI): 61-78% (Willemsen et al., 2015)).   
The genetic basis of depression is more difficult to determine, with 
twin studies estimating the heritability at about 37% (95% CI: 31%-42% 
(Sullivan, Neale, & Kendler, 2000)).  Two studies have, however, reported 
higher heritability in females than in males (40% versus 30%; 42% versus 
29% respectively) and sex-specific genetic effects (Kendler, Gardner, 
Neale, & Prescott, 2001; Kendler, Gatz, Gardner, & Pedersen, 2006). 
Depression is further complicated by its high clinical heterogeneity. There 
is suggestion that gene-environment interaction may influence the risk for 
depression, although this effect was not replicated in a meta-analysis 
(Risch et al., 2009).  
T2DM and depression share common risk factors.  This observation 
could be purely the result of coincidence, or because the two disorders 
share a common biological pathway.  For example, people with diagnostic 
depression have increased levels of inflammation, hyperactivity in the 
hypothalamic-pituitary adrenal (HPA) axis and sympathetic nervous 
system. This is also observed in people with T2DM, suggesting a common 
biological pathway between T2DM and depression.  Other findings include 
a tryptophan hydroxylase polymorphism being associated with both 
metabolic disorders, and insulin resistance in individuals with depression 
(Chiba et al., 2000; Kloiber et al., 2010).  In addition, inflammatory 
markers, such as C-Reactive Protein, have been associated with depressive 
symptoms in individuals with newly diagnosed T2DM (Laake et al., 2014).   
It is therefore possible the T2DM-depression association can in part be due 
to shared biological pathways.   
T2DM and depression are global public health concerns.  Finding a 
genetic overlap between T2DM and depression would provide more direct 
evidence that the epidemiological association observed was due to 
biological factors. It would also advance our knowledge of their 
pathogenesis, contribute to the search for subtypes of depression, and 
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adapt epidemiological methods for multi-morbid conditions.  Although 
predicting genetic liability for complex traits is currently of limited clinical 
value, genetic profiling may one day allow us to stratify patients based on 
outcomes.  For example, identifying individuals with T2DM who are at 
high risk for developing depression would allow appropriate interventions 
to be recommended.  In the long term, a greater knowledge base about 
T2DM and depression will enable us to develop more effective treatments 
for patients with both conditions and to study why depression is common 
in other chronic conditions such as obesity.  It is therefore important to 
review the current literature on the genetic basis of the T2DM-depression 
association.     
1.5 Evidence from family studies 
Family history is a useful first approach in capturing the joint 
contribution of genetic and environmental factors to a condition, or the co-
morbidity between conditions (familial effects).  To date, there has been 
one family study of T2DM and depression published (Pravin, Malhotra, 
Chakrabarti, & Dash, 2006).  It is a cohort study based in India, with a 
sample of 50 patients of T2DM and 481 of their first-degree relatives.  The 
morbid risks for depression in first-degree relatives of probands of T2DM 
were found to be similar to the general population in other studies.  There 
was, however, no comparison group, and individuals with any lifetime 
history of psychiatric disorders were excluded, leading to a low prevalence 
of depression (1.0%).  Another similar study reported that the number of 
generations of diabetes in the family as a good predictor of child depressive 
symptoms (Irving et al., 2008).  Family studies do not, however, 
differentiate between which factors contribute to first-degree family 
members being similar, since relatives share both genes and environment. 
Any familial effect observed could therefore be due to both genetic and/or 
environmental influences.  
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1.6 Evidence from twin studies   
Twin studies provide a unique approach in investigating genetic 
influences on complex traits or disorders; as twins are matched for age, 
genetic factors and a range of covariates in their shared environment, such 
as parenting style and education.  Twin study uses the ratio of disease 
concordance between monozygotic (MZ) and dizygotic (DZ) twins to 
estimate the most likely effects of genetic (heritability), common and 
individual-specific environmental factors.  In simple terms, the method 
uses the ratio of cross-disorder concordance between MZ and DZ twins to 
approximate the genetic and environmental correlations between 
disorders.  Genetic correlation estimates the degree to which genetic 
factors affect both disorders, and is independent of their individual 
heritability estimates. A high genetic correlation does not therefore imply 
a high impact of genes on the observed correlation between the conditions, 
and the actual heritability estimates for each disorder needs to be taken 
into account. 
There have been two twin studies investigating common genetic and 
environmental vulnerability to diabetes and depression.  The Vietnam Era 
Twin Study of Aging consists of MZ and DZ twins who served in the United 
States military during the Vietnam era (1965-1975; n=1237) (Scherrer et 
al., 2011).  It reported a moderate genetic correlation between T2DM and 
depression, with a broad confidence interval (0.19 (95% CI: 0-0.46)).  The 
finding is difficult to interpret, given the sample was restricted to males 
aged 50-59 who were involved in military service. The Screening Across 
the Lifespan Twin Study consists of MZ and DZ twins aged 40 years or 
older recruited from the Swedish Twin Registry (n=37043) and concluded 
there was significant environmental correlation (0.54 (95% CI: 0.02-0.88)) 
between T2DM and depression (Mezuk, Heh, Prom-Wormley, Kendler, & 
Pedersen, 2015).  Both studies do not support a common genetic pathway 
hypothesis. Higher rates of co-morbid T2DM and depression have been 
observed in females compared to males (Ali, Stone, Peters, Davies, & 
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Khunti, 2006; Alonso-Moran, Satylganova, Orueta, & Nuno-Solinis, 2014; 
R. J. Anderson, Freedland, Clouse, & Lustman, 2001), with a meta-
analysis reporting a higher prevalence of depression in females with T2DM 
(23.8%) than males (12.8%; (Ali et al., 2006). Clearly, twin modelling 
incorporating sex differences is needed. 
1.7 Evidence from molecular genetic studies 
The revolution in genomics – the ability to rapidly sequence DNA 
and conduct GWAS - has uncovered many genetic contributions to the 
development and progression of complex traits.  To date, over 120 single 
nucleotide polymorphisms (SNPs) predisposing to T2DM and diabetes-
related traits have been discovered (Prasad & Groop, 2015).  These 
variants are associated with a small risk of developing T2DM (odd ratios 
(OR): 1.0 - 1.2), and in sum capture a small proportion of the genetic 
component of the disease.   The strongest association is observed in the wnt 
signalling pathway member, transcription factor-7-like 2 on chromosome 
10 (Grant et al., 2006; Kildemoes, Sorensen, & Hallas, 2011; S. Purcell, 
2002).  It is 1.5 times more common in patients than in controls, conferring 
an approximately 40% increased risk for T2DM.   Rare variants have been 
associated with T2DM, but a recent analysis using empirical and 
stimulated data suggests rare variants are unlikely to be an important 
source of contribution to the heritability of T2DM, in comparison to 
common variants (Fuchsberger et al., 2016).  
For depression, GWAS have been unable to identify any 
reproducible associations signal until recently.  A meta-analysis did not 
identify any genome-wide significant finding (Ripke et al., 2013), with the 
authors attributing the negative finding to the inherent heterogeneity of 
the phenotypes, and insufficient power due to the high prevalence rate of 
depression in the general population. Fifteen novel SNPs for depression 
have since been identified in individuals of European descent using self-
report data (Hyde et al., 2016), whereas a study in Chinese females with 
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severe depression has identified two loci that are rare in Europeans 
(CONVERGE, 2015).   In addition, a rare missense Asn396Ser mutation in 
the endothelial lipase gene has recently been implicated in the 
pathogenesis of depressive symptoms in a large population-based cohort 
(Amin et al., 2016).     
A range of T2DM-related SNPs have been suggested to be associated 
with depression.  For example, the Pro12Ala variant of the peroxisome 
proliferative-activated receptor γ2 gene has been implicated in 
inflammation, depression, type 1 and 2 diabetes (Eftychi et al., 2004; Ji-
Rong et al., 2009).  A locus involved in the circadian gene CRY2 has been 
associated with both T2DM (Dupuis et al., 2010) and major depressive 
disorder with seasonal pattern (Lavebratt et al., 2010).  A small case 
control study has found individuals with depression have reduced 
expression of FADS1, a gene involved in long-chain polyunsaturated fatty 
acids biosynthesis and T2DM, compared to controls (McNamara & Liu, 
2011).  Depressive behaviours have also been observed in adult mice with 
Insulin-like growth factor-1 knock-out, a gene also implicated in T2DM 
(Mitschelen et al., 2011).  In addition, SNPs associated with leptin, a 
peptide hormone from adipose tissue, has been linked with response to 
antidepressant treatment (Kloiber et al., 2013) and T2DM (Hara et al., 
2014).   
Genotypes for α-2A adrenoceptor (ADRA2A) and melatonin receptor 
1B (MTNR1B) have been associated with raised plasma glucose, a T2DM-
related trait (Dupuis et al., 2010) (Manning et al., 2012).  The ADRA2A 
genotype has been suggested as a predictor of treatment outcome in people 
with depression (Kato et al., 2015), and sex-difference has been reported 
between the activity of the HPA-axis and the ADRA2A genotype (Haefner 
et al., 2008). Genetic polymorphisms and mRNA expression of the 
MTNR1B, on the other hand, has been demonstrated to play a significant 
role in patients with recurrent depression (Galecka et al., 2011).  Studies 
have also indicated a role of the FTO genes in T2DM and body mass index 
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(BMI) (Frayling et al., 2007; Mahajan et al., 2014) and a meta-analysis 
showed a significant inverse association between the FTO rs9939609 A 
variant and depression (Samaan et al., 2013).  Findings from molecular 
genetic studies provide some tentative evidences of the potential of T2DM-
predisposing genes on depression. 
1.8 Evidence from statistical genetics using 
GWAS 
Both T2DM and depression are likely to be polygenetic in nature, 
with hundreds of susceptible alleles of small effects.  T2DM risk alleles 
may contribute small increments in depression risk, and vice versa.  A 
polygenic score approach allows the cumulative effect of multiple T2DM 
genetic risk variants on depression status to be analysed, clarifying 
whether a genetic predisposition to T2DM might be related to depression 
and vice versa.  In parallel to this thesis, the T2DM-depression association 
was examined in two GWAS datasets (Clarke et al., 2016; Samaan et al., 
2015).  Both concluded that there is little evidence of a genetic overlap 
between T2DM and depression.  The EpiDREAM study examined the 
unidirectional association between 20 T2DM SNPs and depression case-
status in 17404 individuals who were at risk for developing T2DM 
(Samaan et al., 2015).  The Generation Scotland study examined the 
shared aetiology between T2DM and depression using polygenic scores and 
Mendelian Randomization in a population cohort of 21516 individuals 
(Clarke et al., 2016).  
There are, however, caveats with both studies, making their 
findings difficult to generalise.  The EpiDREAM study only examined 20 
SNPs associated with T2DM, and over 120 SNPs have been identified with 
T2DM and related traits at GWAS significant level (Prasad & Groop, 
2015). Thus, 20 SNPs are likely to capture only a very small proportion of 
the genetic component of T2DM.  The Generation Scotland study, on the 
other hand, only has 915 individuals with T2DM.  Further research needs 
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to be conducted in cohorts with larger sample size and non-Western 
populations.  In addition, a recent study has demonstrated a genetic 
overlap between BMI-polygenic scores and atypical depression, defined by 
increased appetite or weight, but not typical depression .   Given the 
heterogeneity of depression, the degree of variance in depression subtypes 
which can be explained by the additive effects of common SNPs associated 
with T2DM needs to be explored.   
Linkage disequilibrium (LD) score regression has been applied in 
one study to estimate genetic correlations among 24 complex traits, 
including T2DM and depression. It uses the summary statistics from 
Diabetes Genetic Replication And Meta-analysis Consortium (DIAGRAM) 
and Psychiatric Genomics Consortium-Major Depressive Disorder Stage 1 
(PGC-MDD-1) and estimated a non-significant, positive genetic correlation 
between T2DM and depression (rg (standard error): 0.051 (0.117), 
p=0.666). If there is genetic heterogeneity between cohorts, estimates from 
LD score regression analysis can be biased downwards.  Given both 
DIAGRAM and PGC-MDD-1 consist of multiple cohorts, it will be useful to 
apply the LD score regression in one large population cohort to estimate 
the genetic correlation between T2DM and depression. 
1.9 Overview of thesis  
The objective of this thesis was to identify whether there is a genetic 
overlap between T2DM and depression using three complementary 
approaches: i) structural equation modelling in twin data, ii) polygenic 
score analysis on case-control data and iii) LD score regression on 
summary-level GWAS data (Figure 1-1).  The statistical methods involved 
are discussed in chapters 2 and 5 respectively.   
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Figure 1-1 PhD thesis chapter summary 
 
For the first approach, I explored the T2DM-depression link using 
two large, population-based Scandinavian twin registries (Swedish and 
Danish twin registries; chapter 3).  To examine whether our findings are 
generalizable to non-Western populations, I applied structural equation 
modelling to the Colombo Twin and Singleton Study Phase 2 (COTASS-2; 
chapter 4), given that heritability only refers to a particular population 
and environment.   
For the second and third approach, we focused on GWAS datasets, 
as consistency of a finding across different sample populations and 
methodologies is essential in order to reduce sampling error and for a more 
robust conclusion to be inferred.  The population-based deCODE cohort 
was used as an exploratory study to examine the genetic overlap between 
T2DM and depression using the polygenic score approach (chapter 6).  I 
also performed secondary analysis, as it is unclear whether the genetic 
overlap between T2DM and depression differ with age, sex and BMI.  
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I then validated these findings in the UK Biobank cohort (chapter 
7).  I also estimated the genetic correlation between T2DM and depression 
using LD score regression in the UK Biobank cohort.  In order to dissect 
the heterogeneous nature of depression, I then investigated the association 
between specific depressive symptoms and T2DM-polygenic scores in the 
Psychiatric Genomics Consortium Major Depressive Disorder Phase 2 
(PGC-MDD-29) study (chapter 8).   
Given the inherent heterogeneity of the studies included in this 
thesis, a comprehensive description of the various definitions used for i) 
T2DM and depression phenotype and ii) T2DM and depression polygenic 
scores is summarised in Table 1.1.
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Table 1.1 Summary of measures used by thesis chapter. 
 Type 2 diabetes definition Depression definition  Type 2 diabetes 
genetic risk scores 
definition  
Depression genetic 
risk scores definition 
Chapter 3 
Swedish twin registry Primary diagnosis of type 2 diabetes 
((International Classification of 
Disease (ICD) 8th, 9th and 10th 
edition); hospital registry data 
Primary diagnosis of depression 
(ICD 8th, 9th and 10th edition); 
hospital registry data 
NA NA 
Danish twin registry Primary diagnosis of type 2 diabetes 
(ICD 8th and 10th edition); hospital 
registry data 
Primary diagnosis of depression 




Colombo Twin and 
Singleton Study  
Primary diagnosis of type 2 diabetes; 
self-report 
Beck Depression Inventory; self-
report 
NA NA 
Chapter 6     
deCODE Primary diagnosis of type 2 diabetes; 
clinical records  
Primary diagnosis of lifetime 
depression (Diagnostic and 
Statistical Manual of Mental 
Disorder (DSM) 4th edition and ICD 
10th edition); structured diagnostic 













UK Biobank A combination of i) medical 
diagnosis, ii) age at first diagnosis 
and iii) use of oral anti-diabetic 
medications; self-report to define 
type 2 diabetes and differentiate 
form type 1 diabetes.  
A combination of i) primary 
diagnosis of depression; (ICD 10); 
inpatient hospital episode data or ii) 
previous visit to a General 
Practitioners/psychiatrist for stress, 
anxiety or depression, and at least 
one period of depression/anhedonia 
lasting at least two weeks; self-
report 
DIAGRAM Stage 1 
 
PGC-MDD Phase 2 
(PGC-MDD-29) study 
Chapter 8 
PGC-MDD-29 NA Primary diagnosis of lifetime 
depression (DSM-IV);   
structured diagnostic interview 
 





T2DM and depression are among the leading causes of morbidity 
and mortality globally.  The resultant societal costs of medical care and 
lost productivity have major public health impacts.  A better 
understanding of the mechanisms underlying the association is therefore 
of high clinical and scientific relevance.  There are real opportunities for 
developing novel therapeutic modalities, while facilitating the 
development of stratified medicine for people with T2DM and depression, 
by contributing to the research for targeted treatment of T2DM subtypes 
that have worse prognosis.  Unravelling the genetic predisposition to 
T2DM and depression is a major challenge but presents an exciting 
opportunity to further our understanding of the genetic architecture and 
biological mechanisms underlying T2DM and depression across different 
populations.   
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Chapter 2  
Structural equation modelling of twin data 
 
 
“Melancholy is the happiness of being sad.”  
~ Victor Hugo, The Toilers of the Sea 	 	
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2.1 Overview 
The epidemiological association of type 2 diabetes (T2DM) and 
depression can be attributed to genetic and environmental sources. 
Advanced statistical methods using genetically sensitive data allow us to 
estimate the extent to which the two disorders are associated due to 
overlapping genetic and/or environmental factors.  The classical twin 
method is a valuable study design in behavioural genetics, as monozygotic 
(MZ) and dizygotic (DZ) twins provides a natural window into the aetiology 
of a trait and the overlap between traits.  In this chapter, we will focus on 
the principles underlying structural equation modelling in twin data.  
2.2 The classical twin design  
The classical twin method is designed to estimate the relative 
genetic and environmental contributions to the variance of a trait/disorder 
(Martin, Boomsma, & Machin, 1997).  It has three assumptions; i) MZ 
twins share 100% of their genes in common while DZ twins share on 
average 50% of their segregating genes (additive genetic effects), ii) MZ 
and DZ twins are correlated for shared environmental influences to the 
same extent (equal environment assumption) and iii) mating in the 
population occurs at random (non-assortative mating). Therefore, if a 
behaviour is genetically influenced, a greater similarity in that behaviour 
among MZ than DZ pairs would be observed.   
In the most basic twin model, phenotypic variation (VP) is assumed 
to arise from three sources: i) additive genetic factors (A), ii) common 
environmental factors (C), and iii) unique environmental factors (E). C 
serves to make twins (and all members of the same family) more similar to 
one another, while E tends to make the individuals in a family (or in twin 
pairs) less similar.  Twin data allows us to estimate the heritability of 
complex traits. 
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2.3 What is heritability?  
Heritability (h2) is defined as the proportion of VP due to variation 
in genetic factors (VG; ℎ# = %&%' ), that is the proportion of individual 
differences for a trait in a certain population due to genetic differences 
between individuals. Genetic factors consist of several subcategories, 
including additive variance (VA), dominance variance (VD), and epistatic 
variance (VI; VG = VA + VD + VI).  Together, they reflect heritability in the 
broadest sense (broad-sense heritability).  The narrow-sense heritability 
includes only genetic variation due to additive genetic values (VA; ℎ# = %(%'	).   
Similarly, the proportion of VP due to variation in common environmental 
factors (Vc) and unique environmental factors (VE) are summarised as  )# =%*%'  and +# = %,%'  respectively.   
2.4 Univariate Genetic Analysis 
The equal environment assumption underlying the classic twin 
design implies that any excess of similarity between MZ and DZ twins is 
due to the greater proportion of genetic factors A being shared by MZ twins.  
Therefore, if the MZ correlation is twice as large as the DZ correlation 
(-./ > 2-2/), there is evidence of additive genetic effects.  If the MZ 
correlation is less than twice as large as the DZ correlation (-./ < 2-2/), 
there is evidence for common environmental effects.  If there is no MZ and 
DZ correlation, there is evidence for unique environment effects only.  The 
magnitudes of these correlations reflect the size of the relationship 
between the underlying factors. 
In the full ACE univariate model, MZ and DZ twins are assumed to 
have different degrees of correlation for the genetic factors A but the same 
degree of correlation for the common environmental factors C.  The 
correlations between genetic factors A will be 1 for MZ and 0.5 for DZ 
twins, whereas the correlations between common environmental factors C 
39 
will be 1 for both MZ and DZ twins.  Unique environmental factors E are 
not correlated for MZ or DZ twin (Figure 2-1).  
 
Figure 2-1 A path diagram for the basic ACE univariate twin model. 
Observed variables for twin 1 and twin 2 are shown in rectangles. Latent (unmeasured) 
variables are shown in circles.  A single-headed arrow indicates a direct influence of one 
variable on another (causal paths).  A double-headed arrow between two variables 
indicates a correlation without any directional relationship.  A indicates additive genetic 
factors; C shared environmental factors; E is unique environmental factors and a, c, e are 
path coefficients for A, C and E factors respectively. The correlations between i) additive 
genetic factors A are set at 1 for MZ and 0.5 for DZ twins and ii) common environmental 
factors C are set at 1 for both MZ and DZ twins.  
 
 
Path analysis can be used to derive predicted variance and 
covariance for twin models.  For the basic univariate twin model (Figure 
2-1), the variance of the phenotype is the sum of the square of all paths 
pointing to it 5# + )# + +# . The covariance between twin 1 and 2 is the 
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product of the paths linking the phenotype via A, C and E respectively.  
Therefore, the genetic covariance for MZ twins is 5 ∗ 1 ∗ 5 = 	5#	and for 
DZ twins, it is 5 ∗ 0.5 ∗ 5 = 0.55#, whereas the covariances due to C is c# 
for both MZ and DZ twins respectively. E does not contribute to the 
covariances between twins.  Given the total covariance between two traits 
is the sums of all the paths connecting them via A and C, the expected 
variances and covariances of the traits within MZ and DZ twins can then 
be written as: 
Cov for MZ =  =># + =?# + =@#	 =># + =?#	=># + =?# =># + =?# + =@#	  
Cov for DZ = =># + =?# + =@#	 0.5=># + =?#	0.5=># + =?# =># + =?# + =@#	  
The Falconer’s formula (Falconer & Mackay, 1996) can be used to estimate 
all standardized sources of variance. Broad-sense heritability (h2), c2 and 
e2 are estimated by exploiting the difference in correlation between MZ 
(-./) and DZ (	-2/ ) twins in the following way: ℎ# = 2	(-./ − -2/)	)# = 2-2/ 	− -./		 or		 rMZ	–	h2	e# = 1 − h# −	c#	
2.5 Bivariate Genetic Analysis 
The research question for this project is whether there is a genetic 
overlap between T2DM and depression.  We therefore extend the model-
fitting approach to bivariate genetic analysis.  The observed correlation 
matrix is extended to a 4x4 matrix for each of the MZ and DZ twin groups 
(Figure 2-2)  Sections b and d are the within-trait, cross-twin correlations 
for each trait.  We inspect the MZ:DZ ratio of each separately to infer the 
mode of inheritance, as discussed in the “univariate genetic analysis” 
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section.  Section a is the correlation between the two traits, also known as 
phenotypic correlation or cross-trait, within-twin correlation. If this 
correlation is significant, it suggests common aetiology influences (Rijsdijk 
& Sham, 2002).  To determine whether common aetiology is due to genetic 
or common environmental factors, we examine the MZ:DZ ratio of the 
cross-trait, cross-twin correlations (section c in Figure 2-2). If the MZ:DZ 
correlation ratio is 2:1, it indicates that additive genetic effects drive the 
association between the traits, whereas a 1:1 ratio suggests common 
environmental effects drive the correlation between the trait.  If the cross-
trait, cross-twin correlations are non-significant, unique environmental 
effects are likely to be the predominant cause for the observed phenotypic 
correlation (or comorbidity). 
 
Figure 2-2 Logic of bivariate twin analysis for T2DM and depression. 
aCross-trait, within-twin or phenotypic correlation between T2DM and depression. 
bWithin-trait, cross-twin for T2DM. cCross-trait, cross-twin between T2DM and 
depression. dWithin-trait, cross-twin for depression. 
 Twin 1 Twin 2 





   
Depression Cross-trait, 
within-twina 
















The bivariate twin model can partition and estimate variances of 
T2DM and depression into genetic, common environmental and unique 
environmental factors (A, C and E respectively; Figure 2-3).  Path analysis 
can again be used to derive predicted variance and covariance, since the 
covariance between twin 1 and 2 is the product of the paths linking the 
phenotypes via A, C and E respectively.  Therefore, the genetic covariance 
for T2DM is 5JJ ∗ 	1 ∗ 5JJ = 	5JJ#	in MZ twins and 5JJ ∗ 	0.5 ∗ 5JJ =	0.55JJ# in DZ twins. For depression, it is 5#J ∗ 1 ∗ 5#J	  + 5## ∗ 	1 ∗ 5##	   = 5#J					# + 5##					# in MZ twins and 5#J ∗ 	0.5 ∗ 5#J	  + 5## ∗ 	0.5 ∗ 5##	   = 0.55#J					# + 0.55##					#	in DZ twins.  For T2DM-depression, it is 5#J ∗ 	1 ∗ 5##	 = 	5#J5## in 
MZ twins and 5#J ∗ 	0.5 ∗ 5##	 = 	0.55#J5## in DZ twins. The paths for C 
and E follow the same logic. The bivariate Cholesky ACE model is depicted 
in Figure 2-3 and the expected variances and covariances of T2DM and 
depression within MZ and DZ twins summarised in the table below Figure 
2-3.   
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Figure 2-3 Bivariate Cholesky ACE model and expected covariance of T2DM and depression within MZ and DZ twins. 
Observed T2DM and depression shown in rectangles.  
Latent variables are shown in circles.  A double-
headed arrow between two variables indicates a 
correlation without any directional relationship A 
indicates additive genetic factors; C for shared 
environmental factors and E for unique 
environmental factors. a11, c11 and e11 indicate path 
coefficients for A, C and E factors for T2DM, a22, c22 
and e22 for depression, and a21, c21 and e21 for effect of 
T2DM on depression respectively. The correlations 
between i) additive genetic factors A are set at 1 for 
MZ and 0.5 for DZ twins and ii) common 





Twin 1 Twin 2 
T2DM Depression T2DM Depression 
Twin 1 




a11a21+c11c21 a212+a222+c212 +c222 
Twin 2 
T2DM a112 +c112  a112+c112+e112  





Twin 1 Twin 2 
T2DM Depression T2DM Depression 
Twin 1 




0.5a11a21+c11c21 0.5a212+0.5a222+c212 +c222 
Twin 2 
T2DM 0.5a112 +c112  a112+c112+e112  





The expected variances and covariances of T2DM and depression 
can be standardised to generate standardised variance components on the 
paths and correlations between the latent variables for A, C and E factors 
(aDM, cDM, eDM, aDep, cDep, eDep, Ra, Rc and Re respectively. The standardized 
estimates are then represented as a correlated factors model (Figure 2-4).  
The phenotypic correlation (Rph) for T2DM and depression can then be 
calculated as follow:   
!"# = 		 &'(							)	 ∗ 	+& ∗ &',-							)	 	  
+	 /'(							)	 ∗ 	+/ ∗ /',-							)	 	  
+	 0'(							)	 ∗ 	+0 ∗ 0',-							)	 	  
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Figure 2-4 Bivariate correlated factors model. 
Only one twin from each pair is shown. Observed 
phenotype T2DM and depression are shown in 
rectangles.  Latent variables are shown in circles. 
A indicates additive genetic factors; C for shared 
environmental factors and E for unique 
environmental factors. aDM, cDM and eDM indicate 
path coefficients for A, C and E factors for T2DM 
and aDep, cDep and eDep for depression respectively. 
Ra, Rc and Re indicate correlations between the 
latent variables for A, C and E factors respectively.
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2.6 Modelling sex difference 
Sex is an important moderator for genetic and environmental 
effects.  The classical twin design can be extended to accommodate the 
effect of sex on the variance decomposition by incorporating data from the 
following twin groups: i) same sex pairs (MZ-males, DZ-males, MZ-
females, DZ-females) and ii) DZ-opposite sex pairs.  The use of five twin 
groups allows both qualitative and quantitative sex differences in genetic 
and environmental effects to be examined.  In “quantitative sex 
differences”, the same factors affect both males and females but sex 
modulates the magnitude of their effect, with their impact on the 
phenotypes being greater in one sex than the other. This will be 
characterised by different MZ:DZ ratios in male and female same-sex 
twins in the observed data.  In “qualitative sex differences”, different 
factors are involved in males and females. This will be characterised by 
the DZ opposite-sex twin correlation being much smaller than the DZ 
same-sex correlation in the observed data.  
In “quantitative sex differences”, the genetic factors for DZ-opposite 
sex pairs are assumed to correlate in the same way as the DZ-same sex 
pairs.  Thus, if am is the regression coefficient of a phenotype on the 
standardised genotype for males in a univariate sex-limitation model and 
af for females, then the genetic covariance will be 0.5a%			' for DZ-males pairs, 0.5a(		' for DZ-females pairs and 0.5a%		 a(				for DZ-opposite sex twins.  This 
assumption implies that the same set of genes influence the trait in both 
males and females (M.C. Neale & Cardon, 1992), but to a different degree 
as the magnitude of a%			  can be different to a(			.  The same principles apply 
to the common and unique environmental factors, with c%			  differing from c(			and e%			  from e(	 .   
In “qualitative sex differences”, however, there are expected sex-
specific genetic and/or environmental influences to a trait, indicated by the 
smaller (sometimes negative) DZ opposite-sex correlation. To estimate this 
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effect, the correlation between the additive genetic factors in males and 
females (RaMF) in opposite sex twin pairs is freely estimated to determine 
how different it is from the expected 0.5 as in the DZ same-sex pairs.  Thus, 
if RaMF is substantially different from 0.5, it suggests that different genetic 
factors are involved for that trait in males and females, indicating 
qualitative sex differences.   
In bivariate model whereby sex-limitation modelling includes 
opposite-sex pairs, the Cholesky specification, as depicted in Figure 2-3, 
could cause problems. For example, the overall fit of the model may be 
dependent on the ordering of the variables if there are different modes of 
inheritance for the two traits across the sex (M. C. Neale, Roysamb, & 
Jacobson, 2006).  The correlation approach is used to circumvent this 
problem by specifying explicit correlational paths between the A, C and E 
factors of the two traits in the model.  In the “quantitative sex differences” 
model, the correlations between the additive genetic and common 
environmental factors for T2DM and depression across the male and 
females (RaDM_MF; RaDep_MF; RaDM_Dep_MF; RcDM_MF; RcDep_MF; RcDM_Dep_MF) 
are constrained to 0.5 and 1 respectively in the DZ-opposite sex pairs, as 
in the same-sex DZ twin pairs.  In the “qualitative sex differences” model, 
RaDM_MF, RaDep_MF, RaDM_Dep_MF, RcDM_MF, RcDep_MF and RcDM_Dep_MF are 
estimated as free parameters (Figure 2-5).    
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Figure 2-5 A general sex-limitation ACE model depicted for DZ-opposite sex twin pairs.  
Subscript M indicates males; subscript F for females; 
Subscript DM indicates T2DM; subscript Dep for 
depression; A for additive genetic factors; C for shared 
environmental factors and E for unique environmental 
factors.  Path coefficients for A, C and E factors are 
aDM_M, cDM_M, eDM_M for T2DM and aDep_M, cDep_M, eDep_M 
for depression in males and aDM_F, cDM_F, eDM_F , aDep_F, 
cDep_F and eDep_F in females respectively.  Correlations 
between i) additive genetic factors are Ra; ii) common 
environmental factors are Rc and iii) unique 
environmental factors are Re.  In quantitative sex 
difference model, RaDM_MF, RaDep_MF and RaDM_Dep_MF 
are constrained to 0.5 and RcDM_MF, RcDep_MF and 
RcDM_Dep_MF to 1. In qualitative sex difference model, 
they are estimated as free parameters.   
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2.7 Liability threshold model  
The primary variables of interest for this study are the 
presence/absence of clinically diagnosed/self-reported T2DM and 
depression.  Because they are binary variables, a liability threshold model 
was used in the structural equation modelling.  The model assumes that 
multifactorial diseases result from an underlying continuous character 
that is normally distributed in the population (Falconer, 1960). An 
individual will only be affected when his/her position on the liability 
distribution crosses a certain threshold.  In the univariate twin model, 
there is a two-category ordered variable for each twin, namely affected or 
unaffected status in twin 1 and twin 2.  The joint distribution of liabilities 
of twin pairs is assumed to follow a bivariate normal distribution, with a 
mean of 0, standard deviation of 1 and correlation unknown (Rijsdijk & 
Sham, 2002).  These assumptions allow the relative proportion of 
individuals being affected or unaffected within each twin pair to be used 
to estimate the thresholds and correlation between the liabilities.  
Variance decomposition can be applied to liability, with correlation in 
liability being determined by path analysis.     
2.8 Structural Equation Modelling  
Structural equation modelling combines both variance components 
models and path analysis.  It is the method most commonly used to analyse 
twin data.  For this project, it was performed in the statistical software 
packages OpenMx (Verweij, Mosing, Zietsch, & Medland, 2012) in R.  It 
fits the expectations of a model to the observed variances and co-variances 
of the (raw) data and produces the most likely estimates for the model by 
minimizing the differences via a fit function, such as maximum likelihood 
(M.C. Neale & Cardon, 1992). Raw maximum-likelihood allows us to 
handle data that are missing at random (data missingness) in order to 
derive unbiased estimates.  
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Two criteria are used to choose the best-fitting, parsimonious model: 
i) differences in minus twice the log-likelihood (−2LL) yielding a statistic 
equivalent to a χ"-test, with degrees of freedom equal to the difference in 
the numbers of parameters and ii) Akaike’s Information Criterion (AIC) 
with lower values indicating a better balance between explanatory power 
and parsimony (Akaike, 1987). A difference in AIC of at least 10 indicates 
substantial support in favour of the more parsimonious model (Burnham 
& Anderson, 2002). 
2.9 Limitation of the classic twin design 
There has been ongoing debate in regard to the assumption that MZ 
twins share 100% of their genes in common while DZ twins share on 
average 50% of their genes. Whole genome sequencing efforts has provided 
evidences that DNA sequences difference between MZ twins are not large, 
while studies reporting the proportion of identity by descent sharing (the 
true amount of genetic material that DZ twins have inherited from the 
same parents) ranges between 42-58%, averaging at 50% (van Dongen, 
Slagboom, Draisma, Martin, & Boomsma, 2012; Visscher et al., 2007).    
The equal environment assumption has faced more challenges.  It 
has been suggested that MZ twins might share more similar post-natal 
environment compared to DZ twins.  A study using mistaken diagnosis of 
zygosity has, however, suggested that the more similar treatment received 
by MZ twins is not due to their greater phenotypic similarity but as a result 
of their genetic identity, with more similar response being elicited from the 
environment (Kendler, Neale, Kessler, Heath, & Eaves, 1993; Martin et 
al., 1997).  Using MZ twins separate at birth and reared apart can 
potentially address this criticism, but MZ twins who are reared apart are 
rare.  In addition, studies have suggested that pre-natal developmental 
processes might influence the epigenetic resemblance of twins, with MZ 
twins being epigentically more similar than DZ twins owning to non-
genetic causes (van Dongen et al., 2012).  This, in turn, will result in higher 
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MZ correlation relative to DZ correlation, overestimating the heritability 
of phenotypes that are epigenetically regulated.   Further research will 
clarify this hypothesis.  
There have also been concerns that the circumstances of gestation 
are significantly different between twins and singletons, in particular for 
MZ twins (Martin et al., 1997).   This can, in turn, potentially lead to 
certain medical disorders being more common in MZ twins, both at birth 
and later in life (Phillips, 1993).  Studies have found that twins, especially 
MZ twins, experience growth retardation in utero, but such disadvantages 
disappear by the age of 6, with similar mortality among twins and in the 
general population after the age of 6 (Christensen, Vaupel, Holm, & 
Yashin, 1995). 
Another challenge to the classic twin design is that heritability may 
be inflated in twin studies due to suboptimal modelling of the common 
environment component and the effect of non-assortative mating (Golan, 
Lander, & Rosset, 2014). Genome-wide Complex Trait Analysis (GCTA) 
using data from genome-wide association studies (GWAS) of unrelated 
individuals provides an alternative approach for heritability estimates to 
be estimated (Yang, Lee, Goddard, & Visscher, 2011). Heritability 
estimates from GCTA are generally half when compared to twin studies 
(Plomin & Simpson, 2013).  The discrepancy can in part be due to GWAS 
only capturing effects of SNPs with a minor allele frequency of greater 
than 1%. In addition, GCTA does not include non-additive interactions, 
such as gene-gene or gene-environment.   
2.10 Conclusion 
The classic twin design provides is a powerful tool for studying 
biological discordance in individuals with equivalent genetic background.  
The inclusion of DZ opposite-sex pairs allows the effect of sex to be 
examined.  Population based twin registries are highly valuable resources, 
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with many being involved in large GWAS consortia, making an important 
contribution towards understanding the genetic architecture  
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Chapter 3  
Genetic overlap between T2DM and depression 
in Swedish and Danish twin registries  
 
 
“Sorrow compressed my heart, and I felt I would die, and then … Well, then 
I woke up.”  
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4.1 Abstract  
4.1.1 Background 
A genetic overlap between type 2 diabetes (T2DM) and depression 
has been reported in two Scandinavian twin samples.  This question has 
not been addressed in non-western populations.  In this study, we aim to 
examine the aetiology of the T2DM-depression association in a Sri-Lankan 
population, using genetic model-fitting analysis.   
4.1.2 Methods  
The COTASS-2 consists of 2019 singletons, 842 monozygotic (MZ) 
and 1121 dizygotic (DZ) twin pairs. The primary outcomes were self-
reported T2DM diagnosis and Beck Depression Inventory scores.  
Standard bivariate twin models were fitted to estimate the genetic and 
environmental covariance of the two traits.  
4.1.3 Results 
In the best-fitting model, the phenotypic correlation between T2DM 
and depression was significant in females only (0.15 (95% confidence 
interval (CI): 0.09-0.21)).  This association was primarily attributed to a 
significant genetic correlation between the traits (0.52 (95% CI: 0.19-0.98)).  
4.1.4 Conclusions   
A significant genetic overlap between T2DM and depression in a 
non-western population was reported, in the context of a small phenotypic 
correlation. 
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4.2 Background   
T2DM and depression are common disorders with considerable 
impact at personal, societal and national levels.  An association between 
T2DM and depression is well documented in epidemiological studies, with 
up to 60% increased risk for developing T2DM in individuals with 
depression and 15% for incident depression in those with T2DM alone 
(Mezuk et al., 2008; Rotella & Mannucci, 2013).  Depression is significantly 
associated with suboptimal glycaemic control, higher complication rates 
and increased mortality in people with T2DM (De Groot et al., 2001; Katon 
et al., 2005; Lustman et al., 2000). In addition, systematic inflammation, 
hypercortisolism and disturbed immune functions have been 
demonstrated to contribute to the T2DM-depression association (Kan et 
al., 2013; Laake et al., 2014; Renn et al., 2011).  The underlying 
pathogenesis for comorbid T2DM and depression is likely to be complex, 
with both genetic and environmental factors playing a role.  Genetic 
pleiotropy between T2DM and depression might explain some of the 
comorbidity observed. 
Three twin studies have attempted to examine the genetic overlap 
between T2DM and depression.  Two studies reported no evidence of 
correlated genetic factors (Mezuk et al., 2015; Scherrer et al., 2011), 
whereas one reported sex differences in the (genetic) association of T2DM 
and depression in two large Scandinavian populations (Kan et al., 2016).  
All previous twin studies were conducted in Western populations.  
Although the association between T2DM and depression has been observed 
in non-western populations (Arshad & Alvi, 2016; Hashim, Ariaratnam, 
Salleh, Said, & Sulaiman, 2016; Park et al., 2015), its genetic determinants 
have yet to be examined and there are reasons to suggest that these might 
be different.  Compared to western populations, the prevalence of T2DM is 
rapidly increasing, with a younger age of onset and greater mortality 
(Ramachandran, Ma, & Snehalatha, 2010) whereas the prevalence of 
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depression is reported to be lower in non-western populations 
(Demyttenaere et al., 2004).  In addition, previous twin studies have 
indicated that the genetic architecture of depression might be different in 
non-western populations, especially in males (Hur, 2008).  In this study, 
we aimed to examine the genetic overlap of T2DM and depression in a 
South-Asian (Sri-Lankan) twin population sample using sex-limitation 
genetic model-fitting.  
4.3 Methods 
4.3.1 Sample  
The Colombo Twin and Singleton Study (COTASS) is a population 
based sample of twins born in the Colombo district of Sri Lanka, with >90% 
participation rate (Siribaddana et al., 2008).  COTASS-2 is a follow up of 
the original study and was conducted between 2012 and 2014, with >75% 
participation rate (Jayaweera et al., Under revision). In brief, COTASS-2 
was designed to examine the relationship between mental health and 
metabolic risk factors.  Demographic and phenotypic data were collected 
through extensive healthcare questionnaires whereas anthropometric and 
biological data were collected by trained research assistants. 
4.3.2 Outcome variables  
T2DM was defined as self-reported presence of medical diagnosis of 
T2DM.  In addition, fasting blood glucose and HbA1c (glycated 
haemoglobin levels) were collected.  Depression was measured using the 
Beck Depression Inventory (BDI) which captures depressive symptoms 
and severity in the past two weeks (Beck, Steer, & Brown, 1996).  The BDI 
was translated into Sinhalese by a panel of clinical professionals fluent in 
both Sinhalese and English. The questionnaire was cross-culturally 
adapted in wording in order to best describe the questions in their meaning 
(Sumathipala & Murray, 2000). Secondary variables included self-reported 
age and sex.  Zygosity of same-sex twin pairs was based on a standard self-
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report questionnaire measure of similarity (Ooki, Yamada, & Asaka, 
1993).   
4.3.3 Statistical analysis  
The classical twin method has three main assumptions: i) MZ twins 
share 100% and DZ twins share on average 50% of their segregating genes 
(additive genetic effects); ii) MZ and DZ twins are correlated for 
environmental influences to the same extent (equal environment 
assumption) and iii) mating in the population occurs at random (non-
assortative mating).  In a univariate ACE model, individual differences in 
a trait are assumed to arise from: additive genetic (A), common 
environmental (C) and unique environmental (E) influences.  In a bivariate 
ACE model, in addition to the A, C and E components of each trait, the 
phenotypic correlation between two traits can be partitioned into 
correlating additive genetic (Ra), shared environmental (Rc) and unique 
environmental (Re) effects (M.C. Neale & Cardon, 1992).  Having same-sex 
male and female MZ and DZ twin pairs as well as opposite-sex twin pairs, 
allows testing for: i) “qualitative sex differences” where different genetic 
and common environmental factors are involved in males and females; and 
ii) “quantitative sex differences” where the same genetic and 
environmental factors are involved but the magnitude of their effect is 
modulated by sex.  The power to estimate qualitative sex differences is 
based on differences of within-trait and cross-trait correlations in opposite-
sex DZ pairs compared to same-sex DZ pairs, whereas the power to 
estimate quantitative sex differences is based on differential MZ and DZ 
within-trait and cross-trait correlations in same-sex twin pairs (M. C. 
Neale et al., 2006).   
First, a full sex-limitation model was fitted in which the A, C and E 
parameters were allowed to differ between males and females.  This tests 
for quantitative sex differences.  In addition, for opposite-sex pairs, the 
correlations between the A factors and the C factors between males and 
females were estimated freely in succession.  These two models were then 
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compared to the model in which the correlations between the A factors 
were constrained to 0.5 and those between the C factors to 1 in opposite-
sex pairs, respectively.  This allows us to test for qualitative sex 
differences. Equating the male and female parameters allows us to test for 
quantitative sex differences. The free and open source software programme 
OpenMx (Boker et al., 2011) was used for genetic model-fitting analysis on 
combined dichotomous T2DM data, requiring a liability threshold model 
(17), and continuous, log-transformed sex-and age-regressed BDI residual 
scores.  Age effects on T2DM were modelled on the liability threshold 
(scripts available upon request).   
Two criteria were used to choose the best fitting model: i) differences 
in minus twice the log-likelihood (-2LL) distributed as chi-square and ii) 
Akaike’s Information Criterion (AIC), with lower values indicating a better 
balance between explanatory power and parsimony.  A difference in AIC 
of ≥ 10 indicating support in favour of the more parsimonious model 
(Akaike, 1987; Burnham & Anderson, 2002). 
4.4 Results 
4.4.1 Descriptive Statistics 
The CoTASS sample consisted of 3956 twin individuals (1963 twin 
pairs and 30 twin individuals) and 2019 singletons.  The mean age was 
43.0 (standard deviation (SD): 14.3) and BMI was 23.8 kg/m2 (SD: 4.6; table 
1).  There were 471 cases of self-reported T2DM in total.  For the entire 
sample, the mean fasting plasma glucose was 6.0 mmol/l (SD: 2.3).  The 
mean HbA1c was 42.1 mmol/mol (SD: 15.3) as per International Federation 
of Clinical Chemistry (IFCC) units and 6.0% (SD: 1.4) as per Diabetes 
Control and Complications Trial (DCTT) units. For individuals with a 
diagnosis of T2DM, the mean fasting plasma glucose was 8.9 mmol (SD: 
4.3) and HbA1c was 73.8 mmol/mol (SD: 47.0; DCTT: 8.9% (SD: 4.3)).  For 
individuals who did not report a diagnosis of T2DM, the mean fasting 
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plasma glucose was 5.6 mmol/l (SD: 1.4) and HbA1c was 38.8 mmol/mol 
(SD: 9.8; DCTT: 5.7% (SD: 0.9)).   
The recommended diagnostic cut-off for T2DM using HbA1c is IFCC: 
≥48mmol/mol (DCTT: 6.5%) and fasting plasma glucose is ≥7.0 mmol/l.   
Among individuals who self-reported T2DM and biological samples are 
available (n=426), 117 (27.4%) have HbA1c and 164 (38.5%) have fasting 
plasma glucose below diagnostic cut-offs.  Both HbA1c and fasting plasmas 
glucose can be within the normal range among people with well-controlled 
T2DM and therefore, does not exclude T2DM being present.  Among 
individuals who did not report to have a T2DM diagnosis and biological 
samples are available (n=2,967), 219 (7.4%) have HbA1c and 140 (4.7%) 
have fasting plasma glucose below diagnostic cut-offs.  This suggests a 
small proportion of individuals who fulfil the diagnostic criteria for T2DM 
but are unaware of the disease process in CoTaSS-2.  
The mean BDI depression score was 4.9 (SD: 6.2), with 355 
individuals scoring above 13, the cut-off for a clinical diagnosis of 
depression using the BDI.   The BDI scores were positively skewed on 
visual inspection, with a kurtosis of 6.98 which reduced to -0.17 after log-
transformation of the age and sex-regressed scores. In males, the 
phenotypic correlations between depression and i) T2DM, ii) fasting blood 
glucose and iii) Hba1c were 0.06 (95% confidence interval: -0.02-0.14), 0.06 
(0-0.11) and 0.06 (0.01-0.11) respectively.  In females, they were 0.15 (0.09-
0.21), 0.05 (0.01-0.10) and 0.06 (0.01-0.10).  Correlations stratified by 
zygosity and sex are summarised in Table 4-2.  Given the small phenotypic 
correlation between depression and both fasting blood glucose and Hba1c, 




Table 4-1 Descriptive statistics of MZ and DZ twins, stratified by sex in 
COTASS-2. 
 
  Males Females 
Number of paired twins 














Age,  MZ 37.6 (12.5) 39.2 (12.8) 
Mean (SD) DZ 39.3 (13.0) 42.9 (14.0) 
 Opposite-
sex 
40.2 (13.2)  
Number of T2DM cases MZ 40 51 




Beck Depression Inventory,  MZ 3.7 (5.2) 4.6 (5.7) 
Mean (SD) DZ 3.9 (5.5) 5.1 (6.1) 
 Opposite-
sex 
4.6 (6.1)  
Proband wise concordance rate 
for T2DM 
(Number of concordant pair,  















Table 4-2 Correlations for i) T2DM, ii) depression and iii) T2DM–
depression by zygosity and sex in COTASS-2. 
4.4.2 Genetic model-fitting  
First, a sex-limitation ACE model including quantitative and 
qualitative genetic sex differences was fitted (HetACEg: -2LL=15429.91; 
df=7799; AIC=-168.09).  Significance of qualitative genetic sex differences 
was tested by comparing this model to one in which the correlation 
between the A and C factors across males and females in opposite-sex pairs 
were constrained to correlate at 0.50 and 1 respectively, as is the case in 
same-sex DZ pairs (HetACE: -2LL=15432.42; df=7803; AIC=-174.58).  This 
resulted in a non-significant decline in model-fit (HetACEg vs. HetACE: 
χ2(df=4)=1.52; p=0.82), indicating that qualitative sex differences for the 
genetic factors were negligible.  Secondly, a sex-limitation ACE model 
including quantitative and qualitative common environmental sex 
  Correlation (95% CI)  
  Males Females 
Within Trait Cross Twin   
T2DM MZ 0.94 (0.82-0.98) 0.85 (0.70-0.94) 
 DZ 0.44 (-0.03-0.76) 0.35 (0.01-0.62) 
 Opposite-sex 0.44 (0.16-0.65)  
Depression MZ  0.29 (0.15-0.41) 0.36 (0.25-0.45) 
 DZ 0.24 (0.08-0.38) 0.22 (0.07-0.34) 
 Opposite-sex  0.12 (0.01-0.22)  
Cross Trait Cross Twin   
T2DM - Depression MZ 0.12 (0-0.25) 0.21 (0.09-0.32) 
 DZ 0.06 (-0.14-0.25) 0.06 (-0.09-0.21) 
 Opposite-sex -0.12 (-0.25-0.01)  
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differences was fitted (HetACEc: -2LL=15431.33; df=7799; AIC=-166.67).   
Compared to the HetACE model, this model also showed a non-significant 
decline in fit (HetACEc vs. HetACE: χ2(df=4)=0.097; p=1.00).   Thirdly, we 
tested for quantitative sex differences by equating the A, C and E 
parameters across males and females (HomoACE: -2LL=15583.57; 
df=7812; AIC=-40.43).  Compared to the HetACE model, this resulted in a 
significant decline in fit (HomoACEc vs. HetACE: χ2(df=9)=152.15; 
p<0.0001), indicating the importance of quantitative sex differences. The 
best-fitting model is therefore the sex-limitation model with quantitative 
sex differences (Figure 4-1). 
74 
Figure 4-1 Parameter estimates of the bivariate ACE twin model for T2DM and depression in COTASS-2. 
Best-fit sex-limitation bivariate ACE model shown for opposite-sex DZ twin pairs. A indicates additive genetic factors, C common environmental factors, 
and E unique environmental factors; subscript DM indicates T2DM and D depression; M indicates males and F for females.  Asterisks indicate a significant 
pathway.
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Estimates of the standardized additive genetic, common and unique 
environment variance of the traits were different across sex for depression: 
7% (95% CI: 0%-29%), 22% (95% CI: 6%-36%) and 71% (95% CI: 66%-82%) 
respectively in males, and 23% (95% CI: 3%-43%), 13% (95% CI: 0%-31%) 
and 64% (95% CI: 55%-74%) respectively in females. For T2DM the 
estimates were similar across sexes: 83% (95% CI: 31%-98%), 11% (95% 
CI: 0%-61%) and 6% (95% CI: 2%-17%) respectively in males, and 78% 
(95% CI: 34%-94%), 7% (95% CI: 0%-47%) and 14% (95% CI: 6%-29%) 
respectively in females. The genetic correlation between T2DM and 
depression was non-significant in males (0.37 (95% CI: -0.21-0.93) but 
significant in females (0.52 (95% CI: 0.19-0.98)). The significant phenotypic 
correlation in females is mainly due to correlated genetic factors.   
4.5 Discussion 
To our knowledge, this is the first study reporting a significant 
genetic overlap between T2DM and depression in females in a non-western 
population. Our findings in females are consistent with previous reports 
(Kan et al., 2016), with most of the phenotypic overlap (r=0.15; 95% CI: 
0.09-0.21)) observed being due to correlated genetic factors (rg=0.52; 95% 
CI: 0.19-0.98).  Although the magnitude of our genetic correlation is 
substantially higher, the wider confidence interval (0.52 (95% CI: 0.19-
0.98)) overlaps with estimates derived from the Swedish (0.23 (95% CI: 
0.07–0.38)) and Danish (0.18 (95% CI: 0.06–0.31)) twin samples.   
The major differences between our findings and previous reports in 
Western populations are observed for males.  Firstly, the phenotypic 
correlation was non-significant for males in our sample, whereas it is 
significant in both the Swedish (0.13 (95% CI: 0.08–0.14)) and Danish (0.16 
(95% CI: 0.12–0.20)) twin samples.  Secondly, our best-fitting model 
includes the effects of common environment, whereas previous twin 
studies do not (Mezuk et al., 2015; Scherrer et al., 2011). This might, in 
part, be explained by common environmental factors being more important 
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in explaining individual differences in depression for males in non-western 
populations like Sri-Lanka.  The significant effects of common 
environment factors on depression have been previously reported in a 
Korean twin sample of adolescents and young adult males (32%;(Hur, 
2008).  
Our heritability estimates for depression were also significantly 
lower than those reported in a meta-analysis (~37%) (Sullivan et al., 2000). 
A possible explanation is that there is more room for environmental factors 
to explain individual differences in non-western populations, leading to a 
lower heritability estimates.  Previous studies in the Sri-Lankan 
population have identified male-specific environmental factors to play a 
role in depression, namely unemployment, low levels of standard of living 
and living in more heavily urbanised areas (Ball et al., 2010).  Our finding 
of significant common environmental effects in males might therefore 
reflect the differential economic and social pressures between the sexes in 
non-western populations and between western and non-western 
populations in general, and their subsequent effect on developing 
depression.   
In addition to the explanation above, it is possible that a different 
phenotype of depression might be captured when a western instrument is 
used in a non-western population.  A previous study using the Composite 
International Diagnostic Interview has suggested that the same 
underlying phenotype of depression was being studied, since the total 
number of depressive symptoms and pattern of symptoms endorsed were 
similar between the Sri-Lankan and Western populations (Ball et al., 
2010). A study in the UK has reported that people of South Asian origin 
were more likely to disclose somatic rather than psychological symptoms 
when screening for non-psychotic psychiatric illness, although the extent 
of cultural variation in expressing psychological distress remains unclear 
and controversial (Hussain & Cochrane, 2004).   Given that no specific 
measure of environmental factors was included in our analysis, we are 
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merely speculating on the nature and type of environmental factors that 
might contribute to the T2DM-depression association in non-western 
populations.  If our findings are replicated in a larger non-western 
population twin sample, future studies could examine whether male-
specific environmental factors modulate the aetiology of depression and its 
association with T2DM in non-western populations.  Study specific 
differences also need to be considered in interpreting our findings. The 
COTASS-2 sample differs from previous twin studies in the assessment of 
T2DM and depression (self-report questionnaire/diagnosis verses hospital 
registry) and being a younger cohort.  
4.5.1 Limitation  
One major limitation of the study is the reliance on self-report 
questionnaires for assessing T2DM and depression.  For T2DM, we 
explored the use of HbA1c as a proxy marker, but the phenotypic correlation 
with depression was very small in magnitude.   HbA1c is a useful clinical 
biomarker for assessing glycaemic status and guiding treatment decisions 
for people with T2DM. It can, however, be within the normal range among 
people with well-controlled T2DM.  For example, ~25% of individuals with 
T2DM in our study have a HbA1c <48mmol/mol (6.5%), the recommended 
cut-off for diagnosing T2DM.  HbA1c alone might therefore not be a 
sufficiently reliable tool for recognising T2DM, especially during the early 
stages of the disease. In addition, being diagnosed with T2DM, initiating 
and implementing the associated diabetes self-management might have a 
greater impact on the development of depression than HbA1c alone, 
explaining the differential phenotypic correlations between depression and 
i) T2DM diagnosis and ii) HbA1c. 
For depression, the BDI captures depressive symptoms for the past 
two weeks, and is not aimed to establish a diagnosis of major depressive 
disorder.  Information about antidepressant was also not available at time 
of analysis, and thus, it is possible that individuals who were actively 
depressed and receiving antidepressant treatment were included in the 
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COTASS-2 sample. This can potentially affect their responses on the BDI.  
Psychiatric disorders remain under-recognised in Sri-Lanka.  A scarcity of 
mental health resources and stigma have been identified as major barriers 
for communities to seek care (D'Souza & Singh, 2005).  A recent national 
survey of self-reported health in Sri Lanka reported that only 23% of 
individuals reporting to have a mental illness receive any treatment 
(Ministry of National Policies and Economic Affairs, 2014).  In addition, 
the self-report nature of a questionnaire can affect its results due to social 
desirability and respondent educational attainment (Cronbach, 1990). 
Thus, a more comprehensive approach would be to conduct structured 
diagnostic interview to screen for mental illnesses in the COTASS-2 
sample, but it is both time and labour intensive. 
Adopting a multi-informant approach, such as utilising a valid and 
reliable diagnostic interview for depression or cross-validating our 
measures with a clinical registry, could potentially strengthen our finding.  
Our study also utilises cross-sectional data, and thus, we cannot determine 
the extent by which individuals later develop T2DM or depression after 
being recruited into the study. A longitudinal design will allow us to 
examine changes in genetic and environmental influences in the clinical 
course of T2DM.  Lastly, limitations of the classical twin model apply, 
namely the equal environment assumption and the assumption of 
negligible correlations between the A, C and E factors (Golan et al., 2014; 
van Dongen et al., 2012). 
4.6 Conclusion 
Our study strengthens previous reports of genetic factors playing an 
important role in the mechanism underlying the T2DM-depression link in 
females by replicating the finding in a non-western population and thus, 
demonstrating the generalizability of the finding.  Two recent studies 
using a polygenic score approach in GWAS have, however, reported no 
evidence of a genetic overlap between T2DM and depression (Clarke et al., 
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2016; Samaan et al., 2015).  The reason for the discrepancy in findings 
between twin and GWAS studies is currently unclear and it appears that 
we have only begun to uncover the complex genetic underpinning of the 
T2DM-depression association.   
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Chapter 5  
Polygenic Score Analysis and LD Score 
Regression in Genome Wide Association Studies 
 
 
“No truth can cure the sorrow we feel from losing a loved one. No truth, no 
sincerity, no strength, no kindness can cure that sorrow. All we can do is 
see it through to the end and learn something from it, but what we learn 
will be no help in facing the next sorrow that comes to us without warning.”  




Findings from genome-wide association studies (GWAS) have 
opened up opportunities for estimating heritability from unrelated 
individuals, as an alternative to the traditional approaches of family and 
twin studies.  With the increase in power of these large scale GWAS, it is 
becoming ever more informative to analyse the shared genetic aetiology 
between traits.  This has led to growing evidence of shared and distinct 
genetic architectures among neuropsychiatric disorders (Han et al., 2016).  
Two methods that are used to investigate genetic overlap between 
disorders are polygenic score analysis and linkage disequilibrium (LD) 
score regression. Given that both T2DM and depression are considered to 
be polygenic disorders, with epidemiological studies reporting an 
association between them, we have applied both methods in this thesis to 
examine the polygenic component of these complex traits.  In this chapter, 
I will focus on the statistics underling these methods. In brief, polygenic 
score analysis involves building polygenic risk scores for one phenotype 
and examining its association with another phenotype.  Cross-trait LD 
score regression, on the other hand, uses information from LD and 
summary statistics from GWAS to estimate genetic correlation.  
5.2 What is a GWAS? 
A GWA is a method for hypothesis-free testing association between 
genetic variants and a trait using a sample of unrelated individuals.   A 
GWAS may be a case control study, or a population cohort, with trait status 
known.  It typically uses logistic regression to model the relationship 
between genotype and disease status to detect additive genetic effects. 
GWAS usually tests association between single nucleotide polymorphisms 
(SNP) and disease.  SNPs are a common form of variation that span the 
genome.  In GWAS, effect size is often reported as odds ratio (OR), a ratio 
between the odds of having a specific allele in diagnosed individuals (cases) 
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and the odds of having that same allele in healthy individuals (controls).  
Thus, if the odds ratio is greater than 1, the allele frequency is higher in 
cases than controls.  
Technological advances have allowed SPNs to be efficiently and 
accurately genotyped using Illumina or Affymetrics genotyping arrays.  
These arrays predominantly capture common variation in the population, 
and can also be used to infer larger copy number variants.   Given that 
about a million independent association tests are conducted to test 
common variation genome-wide, the multiple testing-correction threshold 
for a significant association is often set at 5x10-8 (0.05/1000000) (Chanock 
et al., 2007).  
Because of the stringent multiple testing-correction threshold, large 
sample sizes are required to ensure that true association signals achieve 
sufficiently small p-values to reach genome-wide significance.  Power has 
been a challenge for psychiatric genetic studies, especially in depression 
(Flint & Kendler, 2014).  The power of a study is a function of its sample 
size, effect size, allele frequencies of risk loci, and population prevalence.   
The idea of an “inflection point” has been proposed, whereby the number 
of significant associations detected in a study increases approximately 
linearly with sample size once a critical minimum sample size is reached 
(Levinson et al., 2014).  Below the inflection point, studies are 
underpowered to detect association with common SNPs, given small effect 
sizes.  For schizophrenia, it is estimated that the inflection point is at 
13000-18000 cases, with an estimate of 4 new GWA-significant SNPs per 
1000 additional cases.  Because of the higher prevalence and lower 
heritability of depression, the inflection point for depression was estimated 
at 75000-100000 cases (Levinson et al., 2014).  The validity of this 
estimation was strengthened by a recent GWAS for depression based on 
self-reported data, which identified 15 genome-wide significant SNPs in a 
sample of 75607 cases and 231747 controls (Hyde et al., 2016).   
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Lack of statistical power as a result from small sample size can lead 
to type II error in conclusions drawn from GWAS.  Statistical algorithms, 
such as the genomic-relatedness-based restricted maximum-likelihood 
implemented in Genome-wide Complex Trait Analysis (GCTA), have been 
developed to estimate the proportion of phenotypic variance explained by 
SNPs for complex traits. These estimates are thought to reflect the upper-
bound of heritability directly derived from genotypes, if type II error is 
responsible for failure to find an association.  These estimates were named 
“SNP-heritability” to distinguish them from the traditional estimates 
based on family data, and because they were extrapolated from the data 
based on genotyped platforms limited to common SNPs (Manolio et al., 
2009; Yang et al., 2011). SNP-heritability are consistently lower than 
heritability estimates from twin studies, and the difference has been 
termed “missing heritability” (Manolio et al., 2009).  Various theories have 
been proposed to explain the missing heritability, including rare variants 
(Zuk et al., 2014), epigenetics (Furrow, Christiansen, & Feldman, 2011), 
and gene-environment interactions (Kaprio, 2012).  Advances in whole 
genome sequencing will identify rare variants and capture a greater 
proportion of causative common SNPs.  This will reduce the magnitude of 
the “missing heritability” to some extent, but the effect of epigenetics and 
gene-environment interactions will remain unexamined and will need to 
be resolved.   
5.3 Hardy-Weinberg equilibrium and LD 
Hardy–Weinberg equilibrium states that allele and genotype 
frequencies are constant in a population across generations in the absence 
of evolutionary influences.  Factors that can disrupt Hardy-Weinberg 
equilibrium include natural selection, non-random mating, genetic 
mutation, genetic drift and gene flow. For example, natural selection will 
favour the expression of alleles that bestowed survival advantage whereas 
non-random mating might lead to a greater expression of recessive 
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phenotypes.  Both will result in changes in allele frequencies in a 
population.  New alleles can be introduced into a population from de novo 
genetic mutations, or as a result of breeding between two populations (gene 
flow).   
The various scenarios described above can lead to LD, a non-random 
association of alleles at two or more loci.  If two loci are independently 
inherited, the haplotype frequencies are equal to the product of their 
corresponding allele frequencies in the population.  The loci are in linkage 
equilibrium.  If the two loci are not independently inherited, then the allele 
carried at one locus can be predicted from the allele at the second locus.  
LD is a measure of the deviation of observed haplotype frequency from its 
corresponding allelic frequencies expected under linkage equilibrium. LD 
therefore reflects the degree to which alleles at two loci are associated and 
is often standardised as the D’ (relative measure of disequilibrium) or 
parameterised as the r2 (squared Pearson coefficient of correlation) 
(Lewontin, 1988).   One of the statistical method, described in this thesis 
and used to estimate trait and cross-trait heritability, is LD score 
regression, which exploits the relationship between LD and GWA test 
statistics.   
5.4 Population stratification  
Allele frequency can be systematically different between cases and 
controls due to ancestral differences, leading to spurious association 
between disease and the genetic variant (population stratification).  This 
is of particular concern in large-scale association studies, as the effects of 
population stratification increases in proportion to the number of samples 
included.  Large studies have sufficient power to identify very subtle 
differences in allele frequency between cases and controls that can be due 
to differences in genetic ancestry, and not due to differences in disease 
status (Reich & Goldstein, 2001).  To control for confounding effect of 
population stratification, variables capturing these differences are 
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included in the logistic regression analysis as covariates.  These variables 
are constructed from principal component analysis (PCA), a statistical 
method designed to account for variability in a dataset with large number 
of measurements by reducing the number of underlying dimensions to a 
few principal components (PCs).  PCA has been therefore used in 
psychiatric genetics to identify differences in ancestry among populations 
and samples (Novembre et al., 2008).  This allows us to address the 
problem of population stratification (Price et al., 2006) and in datasets with 
ancestral differences between samples, the PCs often capture geographic 
information.   
5.5 Quality Control  
Quality control is an essential part of a GWAS, since any error in 
assumptions can affect the distribution of the test-statistics at the extreme 
end while any artefact can bias the estimates.  It is, however, a fine 
balance, since excessive and unnecessary quality control can lead to 
informative (non-random) missingness.  The aims of post-genotyping 
quality control are therefore to minimise sample heterogeneity at an 
individual level and to minimise genotype-calling problem at SNP level.  
Using individuals from the same underlying genetic population for case-
control ascertainment is essential to avoid introducing systematic biases.  
Subsequent assessment of data quality will allow identification of 
substandard markers or/and samples.   
Some authors have advocated implementing quality control on a 
“per-individual” basis before on a “per-marker” basis, as any SNP that is 
removed from the dataset can potentially have an effect on the disease 
being studied (C. A. Anderson et al., 2010).  Per-individual quality control 
of GWA data involves removing any duplicated or related individuals and 
identifying individuals with i) discordant sex classification and ii) missing 
genotype/heterozygosity rate which is an outlier. Identifying discordant 
sex-information informs us to the possibility of error in sample labelling.  
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Genotype information from the X-chromosome provides an easy way to 
check for any discordance with ascertained sex.   
Handling SNP missingness is a particularly important step in 
ensuring quality control for GWAS datasets, as it is strongly related to 
SNP quality and can lead to both false positive and false negative 
association signals (Weale, 2010).  False positive arises if the difference in 
the frequency of called genotypes between cases and controls is driven by 
effects other than the disease (type I error). In contrast, false negative 
occurs if we fail to gather enough statistical power detect a true difference 
in allele frequency between case and controls (type II error). False positive 
is a more likely scenario if the cases and controls were collected and/or 
genotyped differently, whereas excessive missingness could result in both 
false positives and false negatives. A common threshold used for missing 
genotype rate is <2%, whereby SNPs with a genotyping rate ≤98% are 
automatically removed from further analysis.   
SNP missingness is a particular challenge for low frequency 
variants, since genotyping quality tends to deteriorate with rarer variants.  
SNPs with low minor allele frequency (MAF) have less information 
available, making them more difficult to call with current genotype calling 
algorithms.  To ensure quality control, SNPs with MAF<2% are usually 
excluded (C. A. Anderson et al., 2010).  The MAF > 10/n threshold whereby 
n is the number of samples has also been suggested as a plausible 
threshold (Weale, 2010). 
Another method for checking genotyping quality is to examine 
departure from Hardy-Weinberg equilibrium in controls.  It is 
recommended that SNPs which severely deviate from Hardy-Weinberg 
equilibrium are carefully examined, instead of being excluded, since many 
genuine effects, including a strong signal of association, can lead to 
departure from Hardy-Weinberg equilibrium (Turner et al., 2011).  
Extreme departure from Hardy-Weinberg equilibrium is more likely to 
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result from failure of genotype calling and can be used to guide the quality 
control process (Wittke-Thompson, Pluzhnikov, & Cox, 2005). 
5.6 Imputation  
The main goal of imputation is to utilise LD patterns for extraction 
of further genomic information from reference population by predicting 
SNPs which were not genotyped.  This, in effect, increases genotyping 
coverage, allowing individual studies using different genotyping platforms 
and populations to be combined for meta-analysis, thus increasing 
statistical power.  Common SNPs can usually be imputed with high 
quality, since most SNPs are highly correlated with genotyped SNPs, but 
low frequency SNPs are poorly imputed.   
5.7 Polygenic scores approach 
Given that causal genetic variants identified in GWAS only explain 
a small amount of variation in a trait, it necessitated the introduction of 
polygenic scores approach.  GWAS provides estimates of effect sizes, such 
as OR, for each SNP, but even for highly significant SNPs, the odds ratios 
are often < 1.05.   Each SNP therefore explains only a small component of 
the genetic architecture of the disease and is therefore of limited utility for 
prediction on its own.  However, combining information on risk alleles 
across SNPs creates a continuous measure of genetic liability for a disease 
and provides a better predictor.   Polygenic risk scores may be created from 
SNPs that reach genome-wide significance, or by combining information 
on SNPs which capture modest effects but do not reach genome-wide 
significance.  Polygenic risk scores usually use SNPs that meet liberal p-
value thresholds (PT), such as 5x10-5.  A less stringent PT increases the 
number of SNPs being included in the polygenic scores which, in turn, 
increases the ratio of false-to-true positive SNPs.  The polygenic scores 
approach can, however, tolerate inclusion of some false positives, since the 
stringent genome-wide significance threshold commonly used (5x10-8) can 
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lead to many causal variants being discarded (Wray et al., 2014).  In 
addition, an increase in effect size of the polygenic score can also improve 
the statistical power of the study.   
Two datasets are required to conduct a polygenic score analysis; i) a 
base dataset with GWA summary-level statistics, used to define the SNPs 
to be included in a polygenic risk scores, with their effect sizes as weights 
and ii) a target dataset with individual-level genotype data in which scores 
are constructed.  The two datasets should be independent from each other.  
SNPs which are present in both base and target datasets are then 
identified.  In the base dataset, SNPs in strong LD with other SNPs, 
typically based on a pairwise r2 threshold of 0.1 across 250kb, are pruned, 
generating a list of independent SNPs with the strongest evidence of 
association within each LD region.  
The clumped SNPs are then ranked by their association p-values.  
Subsets of clumped SNPs at various PT, typically ranging from <0.001 to 
<0.5, are generated (step 1 in Figure 5-1).  The risk alleles and effect sizes, 
such as odds ratios (OR), for each SNP in the base dataset are added to 
generate polygenic scores for each individual in the target dataset (step 2 
in Figure 5-1).  A polygenic score is therefore the sum of the number of 
trait-associated alleles, weighted by log(OR) estimated from the base 
dataset (S. M. Purcell et al., 2009): !"#$%&'()	+)",&+ = ./0/12 3/  [1] 
where ./ is the effect size, such as log(OR) and 3/ is the number of risk 
alleles at the locus.   
To test whether polygenic risk score predicts disease status in the 
target dataset, a logistic regression between polygenic scores and disease 
status is performed (step 3 in Figure 5-1).  The proportion of phenotypic 
variance explained by a predictor for binary trait can be approximated by 
Nagelkerke’s pseudo R-squared (45 ).  For binary traits, such as disease 
case-control status, we compare the difference in the 45		between the full 
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model (polygenic score and covariates) and the reduced model (covariates 
only) (Nagelkerke, 1991; S. M. Purcell et al., 2009; Wray et al., 2014).  
Covariates typically include genotyping platform, study sample and 
ancestry-informative PCs.  
Figure 5-1 Polygenic score approach. 
The polygenic score approach can be used to test whether the results 
from a GWAS base dataset predict the same trait in a target dataset.  It 
may also be applied to cross-phenotype analysis which is the remit of our 
project.  For example, we used the summary statistics from the stage 1 of 
Diabetes Genetics Replication And Meta-analysis Consortium (base 
dataset) (Morris et al., 2012) to generate T2DM-polygenic scores in 
deCODE (chapter 6).  We then examined whether there is an association 
between T2DM-polygenic scores and the depression case/control status in 
deCODE using logistic regression.   
5.8 LD score regression 
The LD score regression is a statistical method that uses GWA 
summary-level results (B. K. Bulik-Sullivan et al., 2015). When applied to 
a bivariate model, it generates i) SNP-heritability for the two traits of 
interest (ℎ789_2	5 for trait 1 and ℎ789_55  for trait 2 respectively) and ii) SNP-
correlation between the traits	(,<_789).  It should be noted that ℎ789_2	5 and ℎ789_5	5 only captures additive heritability attributable to common genetic 
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variation (Lee, Wray, Goddard, & Visscher, 2011) and thus, reflecting the 
lower bound for the narrow-sense heritability generated from twin studies.  
In LD score regression, LD score is estimated from a reference panel 
and is the sum of r2 between a SNP and its surrounding SNPs.  ℎ7895  is then 
estimated by regressing the association test-statistics of a SNP from LD 
score.  Genetic correlation is estimated by regressing the product of the Z-
scores for SNP-trait association on the LD scores and standardising it by 
heritability estimates.  For SNP variant j, the product of the Z-scores can 
be summarised as: 
= >2?>5? = 	 8@8A	BCD 	#? +	 B8F8@8A	     [2]1 
where G< is the genetic covariance, #? is the LD score, H2 is the sample size 
of study 1, H5 is the sample size of study 2, M is the number of intersecting 
SNPs across both samples, HI is the number of individuals in both samples 
and G is the phenotypic correlation among the overlapping samples.  Zij is 
the Z-score test statistic from study i for association between trait and SNP 
j.   
If study 1 and study 2 are the same study, then N1 = N2 = Ns,	G< =ℎ<5 and G = 1.   Equation [2] then reduces to the genetic covariance between 
a trait and itself which is the heritability, while the test-statistics become 
the product of the Z-scores (K5 = 	 L5).   
From equation [2], the slope of the regression of >2?>5? on LD score (term	 8@8A	BCD 	) allows us to estimate genetic covariance between the two 
studies.   On the other hand, the intercept (term B8F8@8A) is affected by 
sample overlap and shared population stratification.   
                                            
1 Equations are adopted from Bulik-Sullivan et al., 2015 (13).    
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Genetic correlation (,<)	can be generated by normalising the genetic 
covariance, dividing it by SNP-heritability of trait 1 and trait 2, as 
summarised below: ,< ∶= 	 BCSTUV_@A STUV_AA         [3]1 
where ℎ789_25  is the SNP-heritability for trait 1 and ℎ789_55  is the SNP-
heritability for trait 2.  
The concept behind LD score regression is that the effect size 
estimate from a GWAS for a given SNP incorporates the effects of all SNPS 
that are in LD with that SNP.  Therefore, for a trait that is genetically 
influenced, variants that tag more causal variants will have higher LD 
scores and therefore a higher test-statistics, in comparison to variants with 
lower LD scores (heteroscedasticity).  The genome-wide inflation of the 
test-statistics, in turn, allows us to distinguish polygenicity from biases 
due to cryptic relatedness or population stratification, since such affect all 
SNPs equally, regardless of their LD score.  
There are three major advantages of LD regression score. First, it 
only requires summary-level, not individual-level, genotype data unlike 
polygenic score analysis.  Second, it is a method of high computational 
efficiency, and third, it is robust to sample overlap, as all variants are 
expected to be equally inflated regardless of the amount of genetic 
variation each SNP tags (B. Bulik-Sullivan et al., 2015).   The latter is of 
particular importance, as controls are often shared between cohorts in 
GWA meta-analysis for different traits, and disentangling overlapping 
cohorts is challenging.   
5.9 Limitation of the polygenic score and LD 
score regression approaches 
Both polygenic score and LD score regression analysis are statistical 
tools which are developed to maximise the information available from 
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GWAS datasets to inform our understanding of the genetic architecture of 
complex disorders. There are, however, limitations to both approaches.  
For example, polygenic score approach includes contribution from SNPs 
with small effects sizes which do not reach genome-wide significance but 
given the missing heritability of T2DM and depression from GWAS, a non-
significant finding could be a reflection of no association between the 
polygenic scores and trait being examined or a lack of power (type 2 error).  
We will use the statistical software package Additive Variance Explained 
and Number of Genetic Effects Method of Estimation (AVENGEME) 
(Dudbridge, 2013) to estimate the power of the UK Biobank sample 
(chapter 7). 
It should also be noted that a SNP which is GWA significant for a 
trait might not be the causal variant.  It can be a proxy for the causal 
variant, as the causal variant might not be genotyped or imputed because 
of LD.  It might not, therefore, directly impact disease’s susceptibility 
(indirect association).  The threshold chosen for pruning the polygenic 
score approach is relatively stringent (pairwise r2 threshold of 0.1 across 
250kb).  The process is commonly known as clumping, and its aim is to 
select SNPs that are most strongly associated with a trait in the region 
when constructing the polygenic scores but the thresholds set for clumping 
are arbitrary values.  Thus, it is possible to retain multiple SNPs which 
are associated with the same causal variant while discarding correlated 
SNPs driven by independent causal variants (Wray et al., 2014). The 
polygenic score analysis is not currently designed to address this problem 
and studies have reported that SNPs which appear non-significant when 
examined independently could become highly significant when they are 
part of a pathway-based analysis (Peng et al., 2010).   
Overfitting is another common criticism levelled towards the 
polygenic score approach.  It refers to the scenario when a model is more 
complex than necessary and is a serious threat to the validity of a model.  
A model needs a sufficient number of parameters (complexity) to 
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encapsulate the underlying population relationship, but if the complexity 
grows beyond necessity, the model might start to capture noise rather than 
the true relationship.  We will address the overfitting problem by 
restricting the number of PT we examine in each dataset.   
LD score regression, on the other hand, is not well suited to analysis 
of trans-ethnic or admixed populations.  To generate LD scores, a reference 
dataset is required to robustly estimate the LD structure and there is 
currently limited data available for admixture scenarios.  It also does not 
take into account the long-range admixture LD.   Tools are currently being 
developed to estimate heritability for trans-ethnic or admixed populations 
(Brown, Ye, Price, & Zaitlen, 2016).  This is an important development 
since GWAS have mostly focused on populations of Caucasian descent.  In 
addition, trans-ethnic and fine-mapping have proved to be valuable 
avenues for identifying causal variants.  Efforts have recently been made 
to extend methodology across populations with different ancestries (Brown 
et al., 2016).  It will be interesting to examine the genetic overlap between 
T2DM and depression in non-Caucasian populations in the future.  
GWAS uses a binary model for disease; cases and controls, but both 
T2DM and depression have shown extensive clinical and phenotypic 
heterogeneity.  These variations could be due to environmental factors, 
population stratification or different biological processes underlying the 
two diseases.  For this project, we are interested in whether T2DM and 
depression share any genetic aetiology but neither polygenic score nor LD 
score approaches can distinguish whether the sharing of SNPs across 
traits are driven by all individuals (pleiotropy) or a subset of individuals 
who are genetically more similar (heterogeneity). In addition, any 
phenotypic heterogeneity will dilute effect sizes, further reducing the 
power of a study.   We will examine the genetic overlap between T2DM and 
depressive symptoms in order to explore phenotypic heterogeneity further 
(chapter 8).  In addition, advanced statistical methods such as BUHMBOX 
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have recently been developed to facilitate interpretation of observed 
shared genetic architectures (Han et al., 2016).   
5.10 Conclusion 
GWA has provided us with a valuable way to study the genetic 
architecture underlying complex disorders.   Various discoveries from 
autoimmune diseases to metabolic traits have been made through the 
experimental design of GWAS, with many of the detected loci being 
involved in biologically meaningful pathways for the diseases investigated 
(Visscher, Brown, McCarthy, & Yang, 2012).  It has dramatically expanded 
our understanding of genetics of complex traits.  Meta-analysis of multiple 
GWAS datasets has led to the identification of many genetic variants 
associated with common disorders.  Given the small effect sizes of common 
genetic variants for complex traits, statistical methods such as polygenic 
score and LD score regression approaches have made important 
contributions in advancing our understanding of common disorders.  
Various methodological pitfalls remain and statistical genetics remain an 
exciting yet challenging field. 
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Chapter 6  
Examining the T2DM and depression link using 
polygenic scores approach 
 
 
“Pure and complete sorrow is as impossible as pure and complete joy.”  
~ Leo Tolstoy, War and Peace  
 
 
The dataset has been removed due to third party copyright material. 
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An epidemiological association between type 2 diabetes (T2DM) and 
depression has been consistently reported.  Results from twin studies 
examining the genetic overlap between T2DM and depression are 
currently inconclusive.  Both disorders are considered to be polygenic traits 
and the association has not been examined in genome-wide association 
studies (GWAS).   
6.1.2 Methods 
Using the polygenic score approach, we evaluated whether genetic 
susceptibility to T2DM is significantly associated with depression status 
and vice versa in the Icelandic population.  Disorder-specific polygenic 
scores were created from the association summary statistics of Diabetes 
Genetic Replication And Meta-analysis Consortium (DIAGRAM) and 
Psychiatric Genomics Consortium-Major Depressive Disorder Stage 1 
(PGC-MDD-1).  
6.1.3 Results 
T2DM-polygenic scores were not predictive of depression case status and 
depression-polygenic scores did not predict diabetes case status.  The 
associations remained non-significant when adjusted for covariates.  
Secondary analysis suggested that a significant interaction between 
T2DM-polygenic scores and depression-polygenic scores in predicting 
depression case status (p=0.016, R2 explained=0.056%).  
6.1.4 Conclusion 
This study suggests that T2DM-polygenic scores are not a major 
contribution to depression genetic susceptibility nor depression-polygenic 





An association between T2DM and depression has been consistently 
reported in epidemiological studies, with up to a 60% increased risk for 
incident T2DM in people with depression, and 15% increased risk for 
developing depression in those with T2DM (Mezuk et al., 2008; Rotella & 
Mannucci, 2013).  Public health impacts of both are considerable, with high 
personal and societal costs.  The underlying pathogenesis of the T2DM-
depression association is complex and likely to arise from interactions 
between genetic variants, environmental and social factors.  Three twin 
studies have attempted to examine the genetic overlap between T2DM and 
depression.  Two studies suggest there is no evidence for common genetic 
factors in the T2DM-depression association (Mezuk et al., 2015; Scherrer 
et al., 2011), whereas one study using two large population-level samples 
demonstrates significant sex-difference in the genetic overlap (Kan et al., 
2016).   
A recent study using genome-wide association (GWA) data reported 
no association between an unweighted genotype score, comprising of 20 
T2DM predisposing single-nucleotide polymorphisms (SNPs), and 
depression in a cross-sectional multi-ethnic cohort (Samaan et al., 2015).  
The finding is difficult to interpret, since over 120 SNPs have been 
associated with T2DM and diabetes-related traits at GWA-significant level 
(Prasad & Groop, 2015), and thus 20 SNPs are likely to explain only a 
small amount of the phenotypic variance for T2DM. 
The stringent significance threshold used in GWA studies often 
leads to the discarding of causal variants, because studies lack power to 
identify all causative variants for complex traits.  The polygenic score 
approach was developed to address this problem by assessing the pooled 
effect of SNPs.  An individual SNP may capture modest effects but does 
not reach genome-wide significance (S. M. Purcell et al., 2009).  Polygenic 
risk scores construct a single variable for each individual, summarising 
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their genetic liability for disease.  A more stringent threshold yields 
a polygenic score with a smaller number of SNPs of which a higher fraction 
will be more strongly associated with the disorder of interest, whereas 
a less stringent statistical threshold will increase the number of SNPs 
being included.  This, in turn, often increases the effect size of the polygenic 
score and thereby improves statistical power.  
The genetic overlap between T2DM and depression was recently 
examined in the Generation Scotland study using the polygenic scores 
approach (Clarke et al., 2016).  It is a family and population-based study 
with 19858 participants recruited from General Practitioners.  It reported 
no evidence of a genetic overlap between T2DM and depression but only 
915 individuals have a diagnosis of T2DM.   
Other statistical approaches to estimate genetic correlation between 
traits (rg) include the bivariate genomic-relatedness-based restricted 
maximum-likelihood method (Lee, Yang, Goddard, Visscher, & Wray, 
2012) or bivariate linkage disequilibrium (LD) score regression analysis 
(B. K. Bulik-Sullivan et al., 2015).  A recent analysis of the summary 
statistics from DIAGRAM and PGC-MDD-1 using LD score regression 
estimated a non-significant, positive genetic correlation for T2DM and 
depression (rg (standard error (SE)): 0.051 (0.117), p=0.666 (B. Bulik-
Sullivan et al., 2015)).  The LD score regression method only requires 
GWAS summary-level data, but if there is genetic heterogeneity between 
cohorts, the estimate from LDSC regression analysis can be biased 
downwards.  
Current evidence from twin registries and GWAS is therefore far 
from conclusive.  In this study, we therefore aimed to examine whether 
genetic susceptibility to T2DM was significantly associated with 
depression status and vice versa, using polygenic scores in the Icelandic 
population. Given the substantially higher prevalence rates of comorbid 
T2DM and depression in females compared to males (Ali et al., 2006; 
Alonso-Moran et al., 2014; R. J. Anderson et al., 2001), secondary analysis 
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involved stratifying the cohort by sex to evaluate sex-specific genetic risk 
variants.  In addition, visceral obesity has been postulated as a biological 
explanatory link between T2DM and depression comorbidity (Champaneri, 
Wand, Malhotra, Casagrande, & Golden, 2010; Everson-Rose et al., 2004), 
and genetic overlaps between obesity and both T2DM (Grarup, Sandholt, 
Hansen, & Pedersen, 2014) and depression (Hung et al., 2015) have been 
reported  respectively. We therefore also explored the effect of body mass 
index (BMI) on the T2DM-depression association. 
6.3 Methods 
6.3.1 Sample 
deCODE is a population-level database based in Iceland (Gulcher & 
Stefansson, 2001). This study is based on whole-genome sequence data 
from 149838 Icelanders born before 1999 participating in various ongoing 
disease projects at deCODE Genetics, of which 79133 have BMI data 
available.  All personal identifiers of participants, from whom phenotype 
information and biological samples were obtained, were encrypted in 
accordance with the regulations of the Icelandic Data Protection Authority 
using a third-party encryption system. Permission for the study was 
granted by the National Bioethics Committee of Iceland, and the Icelandic 
Data Protection Authority. Written informed consent was obtained from 
all participants. 
6.3.2 Participants  
Lifetime diagnosis of T2DM was confirmed through clinical records.  
Diagnoses of depression were made by clinicians or clinician-administered 
Diagnostic and Statistical Manual of Mental Disorders (DSM) checklist or 
based on the results of a semi-structured diagnostic interview using the 
Composite International Diagnostic Interview.  Thus, cases of depression 
were defined as individuals who met the diagnostic criteria of DSM-3rd 
edition or International Statistical Classification of Diseases -9th and -10th 
edition of major depressive disorders.  All levels of severity of depression 
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[mild, moderate and severe] were included.  Controls were recruited as 
part of various genetic programs at deCODE.  Controls for T2DM were 
drawn from the population (n=140658), whereas controls for depression 
were screened for psychiatric disorders (n=10525).  Full information on 
medical history was unknown unless individuals had participated in 
genetic programs for disorders such as myocardial infarction and obesity.  
6.3.3 Genotyping and imputation 
Genotyping and imputation methods have been described in details 
elsewhere (Gudbjartsson et al., 2015).  In brief, genotyping was carried out 
using Illumina SNP chips. Long-range phasing and imputation was based 
on whole genome sequencing of 2636 Icelanders. SNPs with minor allele 
frequency <0.01% and imputation marker INFO score < 0.8 were excluded.   
6.3.4 Scoring 
T2DM-polygenic risk scores were constructed from the association 
summary statistics of DIAGRAM (34840 cases and 114981 controls) 
(Morris et al., 2012), while depression-polygenic scores used the 
association summary statistics of PGC-MDD-1 (9240 depression cases and 
9519 controls) (Ripke et al., 2013).  Participants from the deCODE cohort 
were excluded from the DIAGRAM datasets.  To account for only 
independent association signals from T2DM-susceptibility and depression-
susceptibility SNPs, LD–based clumping (r2 >0.2 based on the 1000 
Genomes database) was implemented. Polygenic scores were created in 
PLINK (S. Purcell et al., 2007), using the software package PRSice v1.23 
(Euesden, Lewis, & O'Reilly, 2015).  In brief, the polygenic score is the sum 
of the number of risk alleles carried, weighted by the log(odd ratios (OR)) 
(S. M. Purcell et al., 2009).   For each individual, T2DM and depression-
polygenic scores on SNPs with associated p-values ranging from <0.001 to 
<0.5 were generated from DIAGRAM and PGC-MDD-1. 
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6.3.5 Statistical analysis 
All statistical analyses were performed in R (http://www.r-
project.org).  Logistic regression was performed to assess the association 
between i) T2DM-polygenic scores and depression case/control status and 
ii) depression-polygenic scores and T2DM case/control status, adjusting for 
ancestry principal components (PCs), at seven SNP p-value cut-offs (PT: 
0.001, 0.01, 0.1, 0.2, 0.3, 0.4 and 0.5).  In addition, a hierarchical multiple 
regression analysis was performed as a model for predicting T2DM and 
depression case/control status respectively, adding year of birth, sex and 
BMI to the model sequentially.  Secondary analyses examined the 
interaction of i) sex, ii) BMI and iii) T2DM-polygenic risk scores with 
depression-polygenic scores.  From each analysis, the proportion of 
variance in case-control status explained (Nagelkerke's pseudo-R2) and p-
value for the fit of the model was extracted. 
6.4 Results 
6.4.1 Demographics analysis 
The deCODE sample consisted of 69181 males and 80657 females, 
with a mean age of 56.8 years (standard deviation (SD): 20.9) and mean 
BMI of 27.2 kg/m2 (5.2; Table 6-1).  The prevalence for T2DM was 6.1% 
(n=9180) and for depression was 2.9% (n=4282).  Both T2DM- and 
depression-polygenic scores predict their corresponding disorders.  The 
maximum variance explained was 0.47% for T2DM (at PT<0.4, p<10-59) 




Table 6-1 Demographic characteristics of individuals from deCODE. 
ap-values were calculated using χ2 for non-parametric variable and t-test for parametric 
variable; bData were available on a subset of i) 6811 cases and 72322 controls for T2DM 
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6.4.2 Logistic regression 
In the primary analysis, T2DM-polygenic scores were not predictive 
of depression case status and depression-polygenic scores were not 
predictive of T2DM case status (Table 6-2).  The association remained non-
significant when adjusted for covariates of year of birth, sex and BMI 
(Table 6-3).  Secondary analysis suggested that no difference in the 
association between i) T2DM-polygenic scores and depression case status 
or ii) depression-polygenic scores and T2DM case status between the sexes 
(Table 6-4).  The interaction between T2DM-polygenic scores and BMI also 
has no effect on depression case-status, nor depression-polygenic scores 
and BMI on T2DM case-status (Table 6-5).   
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Table 6-2 Association of i) T2DM-polygenic scores with depression and ii) depression-polygenic scores with T2DM in 
deCODE at various PT. 
 i) Association with depression  ii) Association with T2DM 
 T2DM-polygenic scores   Depression-polygenic scores 
 OR (95% CI) R2 explained (%) p  OR (95% CI) R2 explained (%) p 
PT        
< 0.001 0.99 (0.96-1.03) 0.0017 0.678  0.99 (0.97-1.02) 0.0005 0.593 
< 0.01 0.99 (0.96-1.03) 0.0011 0.739  1.00 (0.98-1.02) 1.05 x 10-9 1.000 
< 0.1 1.02 (0.98-1.06) 0.0094 0.323  1.01 (0.99-1.04) 0.0033 0.178 
< 0.2 1.01 (0.98-1.05) 0.0033 0.560  1.02 (1.00-1.04) 0.0054 0.084 
< 0.3 1.00 (0.97-1.04) 0.0005 0.829  1.02 (0.99-1.04) 0.0037 0.152 
< 0.4 1.00 (0.97-1.04) 0.0002 0.888  1.02 (1.00-1.04) 0.0049 0.098 
< 0.5 1.00 (0.97-1.04) 0.0004 0.834  1.02 (0.99-1.04) 0.0038 0.145 
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Table 6-3 Association of i) T2DM-polygenic scores with depression and ii) depression-polygenic scores with T2DM in 
deCODE at various PT, adjusted for year of birth, sex and BMI. 
 
 i) Association with depression  ii) Association with T2DM 
 T2DM-Polygenic Scores   Depression-Polygenic Scores 
 OR (95% CI) R2 explained (%) p  OR (95% CI) R2 explained (%) p 
PT        
< 0.001 1.01 (0.96-1.05) 0.0018 0.700  0.98 (0.96-1.01) 0.0036 0.241 
< 0.01 1.01 (0.97-1.06) 0.0028 0.628  0.99 (0.97-1.02) 0.0005 0.661 
< 0.1 1.02 (0.98-1.07) 0.0136 0.288  1.01 (0.98-1.03) 0.0014 0.475 
< 0.2 1.02 (0.98-1.07) 0.0090 0.388  1.02 (0.99-1.04) 0.0037 0.237 
< 0.3 1.01 (0.97-1.06) 0.0027 0.635  1.02 (0.99-1.05) 0.0038 0.228 
< 0.4 1.01 (0.96-1.05) 0.0011 0.762  1.02 (0.99-1.05) 0.0054 0.151 
< 0.5 1.01 (0.97-1.06) 0.0025 0.649  1.02 (0.99-1.04) 0.0042 0.207 
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Table 6-4 Association of i) T2DM-polygenic scores with depression and ii) depression-polygenic scores with T2DM in 
deCODE, stratified by sex, at various PT. 
 i) Association with depression 
 T2DM-polygenic scores 
 Males   Females 
 OR (95% CI) R2 explained (%) p  OR (95% CI) R2 explained (%) p 
PT  
 
     
< 0.001 1.00 (0.94-1.06) 8.65 x 10-5 0.952  0.98 (0.94-1.03) 0.0082 0.477 
< 0.01 1.02 (0.97-1.09) 0.0173 0.396  0.97 (0.93-1.02) 0.0231 0.234 
< 0.1 1.02 (0.96-1.08) 0.0077 0.573  1.02 (0.97-1.07) 0.0098 0.438 
< 0.2 1.00 (0.95-1.06) 0.0002 0.929  1.02 (0.97-1.07) 0.0070 0.511 
< 0.3 0.99 (0.94-1.05) 0.0014 0.807  1.01 (0.96-1.06) 0.0029 0.674 
< 0.4 1.00 (0.94-1.06) 0.0001 0.940  1.00 (0.96-1.05) 0.0006 0.842 
< 0.5 1.00 (0.94-1.06) s 5.22 x 10-5 0.963  1.00 (0.96-1.05) 0.0006 0.843 
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 ii) Association with T2DM 
 Depression-polygenic scores 
 Males   Females 
 OR (95% CI) R2 explained (%) p  OR (95% CI) R2 explained (%) p 
PT        
< 0.001 1.00 (0.97-1.03) 0.0002 0.822  0.99 (0.96-1.03) 0.0010 0.594 
< 0.01 1.02 (0.99-1.05) 0.0053 0.225  0.98 (0.95-1.01) 0.0059 0.204 
< 0.1 1.02 (0.99-1.05) 0.0043 0.276  1.01 (0.98-1.05) 0.0029 0.376 
< 0.2 1.02 (0.99-1.05) 0.0075 0.150  1.02 (0.99-1.05) 0.0044 0.270 
< 0.3 1.01 (0.99-1.05) 0.0032 0.347  1.02 (0.99-1.05) 0.0051 0.235 
< 0.4 1.02 (0.99-1.05) 0.0040 0.290  1.02 (0.99-1.05) 0.0069 0.167 
< 0.5 1.01 (0.98-1.04) 0.0030 0.363  1.02 (0.99-1.05) 0.0057 0.211 
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Table 6-5 Association of the interaction between BMI and i) T2DM-polygenic scores with depression and ii) depression-
polygenic scores with T2DM in deCODE, at various PT. 
 
 i) Association with depression  ii) Association with T2DM 
 Interaction of BMI-T2DM-polygenic scores   Interaction of BMI-depression-polygenic scores 
 OR (95% CI) R2 explained (%) p  OR (95% CI) R2 explained (%) p 
PT   
 
    
< 0.001 1.00 (0.99-1.01) 0.0005 0.849  1.00 (1.00-1.00) 0.0054 0.160 
< 0.01 1.00 (0.99-1.01) 0.0039 0.590  1.00 (1.00-1.01) 0.0014 0.465 
< 0.1 0.99 (0.99-1.00) 0.0288 0.143  1.00 (1.00-1.00) 0.0001 0.839 
< 0.2 1.00 (0.99-1.00) 0.0147 0.295  1.00 (1.00-1.00) 1.12 x 10-7 0.995 
< 0.3 1.00 (0.99-1.00) 0.0219 0.201  1.00 (1.00-1.00) 0.0003 0.747 
< 0.4 1.00 (0.99-1.00) 0.0198 0.225  1.00 (1.00-1.00) 4.01 x 10-5 0.903 
< 0.5 1.00 (0.99-1.00) 0.0215 0.206  1.00 (1.00-1.00) 3.86 x 10-7 0.990 
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We also examined the interaction of T2DM-polygenic scores and 
depression-polygenic scores in predicting i) depression case-status, with 
diabetes-polygenic scores being fixed at PT<0.4, the threshold whereby it 
explained the maximum variance of T2DM in this sample, and ii) T2DM 
case status, with depression-polygenic scores at PT<0.5, the threshold 
whereby it explained the maximum variance of depression in the deCODE 
sample. 
The interaction explained 0.051% of the variance in depression case-
status, when depression-polygenic scores are at PT<0.3 (p=0.021) but not 
for T2DM case-status (Table 6-6). There was an inverse association 
between the interaction and depression case-status (OR (95% CI): 0.96 
(0.92-0.99)).  The associations were statistically non-significant after 
Bonferroni correction (p<0.0007 for 7 PT and 10 analyses).   To visualize 
these results, interactions were plotted between the T2DM-polygenic 
scores quartiles at the PT with the most significant interaction (PT<0.3; 
Figure 6-1).  Individuals in the first quartile (Q1) have the lowest genetic 
liability for disease, whereas those in the fourth quartile (Q4) have the 
highest.  For individuals with T2DM-polygenic score in Q1, a higher 
depression-polygenic score was associated with a higher risk of depression 
(figure 1; red line).  The associations were similar for the other three 
quartiles (figure 1, Q2 - green line, Q3 - blue line and Q4 - yellow line). 
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Table 6-6 Association of T2DM-polygenic scores and depression-polygenic scores interaction with i) depression and 
depression-polygenic scores at PT<0.5, and ii) T2DM and T2DM-polygenic scores at PT<0.4 in deCODE, at various PT.  
p-value significant at 0.05 
 
i) Association with depression 
with T2DM-polygenic scores at PT<0.4 
 
ii) Association with T2DM 
with depression-polygenic scores at PT<0.5 
 T2DM-polygenic scores and depression-polygenic scores interaction 
 OR (95% CI) R2 explained (%) p  OR (95% CI) R2 explained (%) p 
PT        
< 0.001 1.00 (0.96-1.04) 0.0006 0.809  1.00 (0.98-1.02) 0.0001 0.814 
< 0.01 0.97 (0.93-1.00) 0.0335 0.062  0.99 (0.97-1.01) 0.0009 0.475 
< 0.1 0.96 (0.93-1.00) 0.0425 0.035*  0.98 (0.96-1.00) 0.0058 0.074 
< 0.2 0.96 (0.93-0.99) 0.0486 0.025*  0.98 (0.96-1.00) 0.0054 0.085 
< 0.3 0.96 (0.92-0.99) 0.0513 0.021*  0.99 (0.97-1.01) 0.0019 0.307 
< 0.4 0.96 (0.93-1.00) 0.0424 0.036*  0.99 (0.97-1.01) 0.0018 0.321 
< 0.5 0.96 (0.93-1.00) 0.0390 0.044*  0.99 (0.97-1.01) 0.0015 0.359 
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Figure 6-1 Multiplicative interaction between depression-polygenic scores at PT<0.3 and quartiles of T2DM-polygenic scores 
at PT<0.4.   
Crosses are cases and circles are controls.  
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6.5 Discussion 
In our study, no association was observed between i) T2DM-
polygenic scores and depression case status, or ii) depression-polygenic 
scores and T2DM case status.  Our findings did not support the notion that 
common shared SNPs contribute to clinical diagnosis of T2DM and 
depression in the Icelandic population.   
Our secondary analysis tentatively suggested an association 
between depression case status and interaction between T2DM- and 
depression-polygenic scores.  This appears to be driven by individuals who 
are in the lowest quartile for T2DM-polygenic scores.  This, in part, 
suggests that depression-polygenic scores might have a lesser effect in the 
development of depression in individuals with a greater genetic liability 
for T2DM.  Other factors, such as lifestyle, might have a greater effect.  In 
addition, the mean ages between the cases and controls for both disorders 
are significantly different (T2DM cases: 71.0 (17.0), controls: 55.9 (20.8), 
depression cases: 64.1 (20.0), controls: 55.3 (15.9)), our findings might 
therefore reflect a greater culmination of environmental factors on T2DM 
and depression in older adults that overwhelms the genetic effects.   Our 
results should, however, be treated with caution, given the association was 
statistically non-significant after Bonferroni correction for the number of 
hypotheses tested. 
Depression is thought to be a highly heterogeneous disorder (25), 
with accumulating evidence suggesting different depression subtypes are 
associated with different biological correlates (Hickman, Khambaty, & 
Stewart, 2014; Lamers et al., 2013; Lasserre et al., 2014).  For example, 
one study reported greater inflammation and metabolic abnormalities in 
people with atypical depression, whereas hyperactivity in the 
hypothalamic–pituitary–adrenal axis was observed in people with typical 
depression (Lamers et al., 2013).  Recent research has also demonstrated 
that BMI-polygenic scores are associated with atypical depression 
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(Milaneschi et al., 2015).  We were, however, unable to differentiate the 
various depression subtypes in this study.  It is therefore possible distinct 
polygenic liabilities might underlie the relationship between T2DM and 
depression subtypes.   Future studies need to address the issues of 
heterogeneity in depression while examining the genetic overlap 
underpinning the T2DM-depression link. 
6.5.1 Limitation 
We have included only individuals of Icelandic-ancestry and thus 
cannot report on the generalizability of our findings to other ethnic groups.  
The use of clinically assigned diagnoses might have captured mores severe 
cases, and resulted in individuals who are asymptomatic at the early 
stages of T2DM and/or depression being classified as non-cases, and might 
partly explain the low prevalence of depression observed.  In addition, 
controls were not actively screened for other physical disorders, 
contributing to the conservative nature of the findings. There is a 
discrepancy in the power to detect associations between the two disorders, 
with T2DM-polygenic scores from DIAGRAM explaining 0.59% of the 
variance in T2DM, whereas depression-polygenic scores derived from 
PGC-MDD-1 can only explain 0.20% of the variance in depression.  This, 
in turn, would affect the power of the current study to detect any genetic 
overlap between T2DM and depression, despite its large sample size.  It is 
therefore prudent to use the summary statistics from PGC-MDD Phase 2 
study when publicly available to derive the depression-polygenic scores.  
This would lead to greater power in explaining the variance in depression 
liability. In addition, the polygenic score estimates the genetic influences 
from effects captured by common SNPs.  It is possible that rare variants of 
large effects or epigenetic processes can underpin the T2DM-depression 
link.  A recent study using empirical and stimulated data has, however, 
suggested low frequency and rare variants are unlikely to be an important 
source of contribution to the heritability of T2DM in comparison to common 
variants (Fuchsberger et al., 2016).  Further work is needed to understand 
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the biological underpinning of the T2DM and depression association, and 
the role of sex and BMI.  
6.6 Conclusion 
To conclude, our study did not provide any evidence genetic variants 
associated with depression are associated with T2DM.  There is tentative 
evidence to suggest that depression-polygenic scores might have a lesser 
effect in the development of depression in individuals with a greater 
genetic liability for T2DM.  There remains a need to study the genetic 
overlap between T2DM and depression, as it might elucidate the 
bidirectional association observed in decades of epidemiological studies, 
while shedding light on common phenotypes such as obesity.  
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Chapter 7  
Dissecting the genetic overlap between T2DM 
and depression in the UK Biobank 
 
 
“Nothing thicker than a knife's blade separates happiness from 
melancholy.”  
~ Virginia Woolf, Orlando  
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7.1 Abstract  
7.1.1 Background 
Epidemiological studies have demonstrated an association between 
Type 2 diabetes (T2DM) and depression, and recent twin studies suggest a 
genetic overlap between the two disorders. The aim of this is to 
systematically examine the genetic overlap between T2DM and depression 
using two complementary approaches in the UK Biobank. 
7.1.2 Methods 
We tested whether depression-polygenic scores is associated with 
T2DM case status and T2DM-polygneic scores with depression case-status. 
We also estimated the genetic correlation between the two disorders using 
linkage disequilibrium (LD) score regression. Secondary analyses 
examined the effect of sex, body mass index (BMI) and severity of 
depression.  
7.1.3 Results 
No association between T2DM-polygenic scores and depression case 
status or depression-polygenic scores with T2DM case status was 
observed. The genetic correlation between the two disorders was also 
statistically non-significant.   
7.1.4 Conclusion  
There is no evidence of shared genetic susceptibility between T2DM 
and depression in the UK Biobank. 
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7.2 Background 
Epidemiological studies have consistently reported an association 
between T2DM and depression, with up to 60% increased risk for incident 
T2DM in people with depression and 15% increased risk for developing 
depression in those with T2DM (Golden et al., 2008). Depression is 
associated with adverse effects on diabetes outcomes including suboptimal 
glycaemc control, complications and higher rates of mortality (De Groot et 
al., 2001; Katon et al., 2005; Lustman et al., 2000).  Tentative evidence 
suggests these disorders share common pathophysiological mechanisms.  
For example, inflammatory markers, such as C-Reactive Protein, has been 
associated with depressive symptoms in individuals with newly diagnosed 
T2DM (Laake et al., 2014).  A dysregulated and overactive hypothalamic–
pituitary–adrenal axis has also been postulated as a possible biological 
explanation for the T2DM-depression association (Moulton, Pickup, & 
Ismail, 2015).  
A genetic overlap between T2DM and depression has recently been 
reported in the Danish and Swedish twin registries.  The T2DM-depression 
association is primarily attributed to genetic effects in both sexes in the 
Danish sample but this effect is only observed in females in the Swedish 
sample. In addition, qualitative sex differences in the genetic overlap 
between T2DM and depression was observed, suggesting that different 
genetic factors might be involved across the sexes in explaining the T2DM-
depression association.   
Both T2DM and depression are considered to be highly polygenic, 
whereby the overall genetic contribution to the traits results from the 
combined effects of many genetic variants exerting small individual effects 
(Ripke et al., 2013). Polygenic score analysis involves building genetic risk 
scores from the genetic components of one trait and examining its 
association with a second trait.  Two recent studies using the polygenic 
score approach have concluded that there is little evidence of a genetic 
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overlap between T2DM and depression (Clarke et al., 2016; Samaan et al., 
2015).  There are, however, several caveats with both studies.  The 
EpiDREAM study is a multinational, longitudinal study of 24872 
individuals who were at risk for developing T2DM (9).  It examines the 
unidirectional association between depression and 20 T2DM-single 
nucleotide polymorphisms (SNPs).  Given that over 120 SNPs predisposing 
to T2DM and diabetes-related traits have been discovered, 20 SNPs are 
likely to capture only a small amount of the phenotypic variance for T2DM 
(Prasad & Groop, 2015).  The Generation Scotland study is a family and 
population-based study with participants recruited from General 
Practitioners throughout Scotland.  Genome-wide genotype data were 
available for 19858 individuals but only 915 individuals have a diagnosis 
of T2DM (Clarke et al., 2016).  In addition, the effect of sex was not 
examined, despite a meta-analysis reporting a higher prevalence of 
depression in females with T2DM (23.8%) than males (12.8%; (Ali et al., 
2006).  In this study, we aim to investigate the genetic aetiology of the 
T2DM-depression association in the UK Biobank (Sudlow et al., 2015), 
using the polygenic scores and LD score regression approaches, in order to 
clarify whether a genetic predisposition to T2DM might be related to 
depression and vice versa.  
7.3 Methods 
7.3.1 Sample 
The UK Biobank is a large, prospectively-sampled population cohort 
of 502656 adults aged 40-69, designed to examine the genetic and 
environmental determinants of diseases in adulthood (Sudlow et al., 2015).  
Full details on study design, survey methods and data collection has been 
reported elsewhere (UK Biobank, 2010).  In brief, participants were 
selected through national patient registers based on distance from their 
nearest UK Biobank assessment centre.  Demographic and phenotypic 
data was collected through extensive healthcare questionnaires, 
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interviews with nursing staff and electronic health records between 2006 
and 2010. Biological samples were also collected for genotyping.  
7.3.2 Primary variables derived from UK Biobank 
T2DM case status was defined by self-reported medical diagnosis as 
previously described with slight modification (Peters, Huxley, & 
Woodward, 2016). In brief, an algorithm used the following information to 
define T2DM and to differentiate from type 1 diabetes: i) self-reported 
medical diagnosis of diabetes, ii) age at first diagnosis (≥30 years old for 
South Asian and African Caribbean and ≥36 years old for European) and 
iii) the use of oral anti-diabetic medications.  
The presence of depression was based on either: i) a primary 
diagnosis of depression from the inpatient hospital episodes data (ICD 10 
subchapters F32 and F33) or ii) a self-reported diagnosis as previously 
described (Smith et al., 2013). In brief, the latter case definition required 
a previous visit to a General Practitioners/psychiatrist for stress, anxiety 
or depression, and at least one period of depression/anhedonia lasting at 
least two weeks. Depression controls were defined as the absence of any 
hospitalisation/self-report diagnosis of depression, anxiety, bipolar 
disorder, psychosis, multiple personality disorder, autism or intellectual 
disability, and no previous usage of antidepressant, anxiolytic, mood 
stabilising or anti-psychotic medication.  
7.3.3 Secondary variables derived from UK Biobank 
Secondary variables included age, sex, ethnicity, BMI and previous 
history of severe depression. Demographic data were collected from 
baseline self-report questionnaires and BMI was derived from baseline 
physical measurements obtained by trained staff. Height was measured 
using a Seca 202 height measure and weight using a Tanita BC-418 MA 
body composition analyser.  Severe depression is defined as having more 
than one episode of depression and receiving care from a psychiatrist 
during their lifetime as self-reported by participants.   
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7.3.4 Genotyping, imputation and quality control  
The interim release of the genotyping data for UK Biobank consists 
of 152734 individuals.  Genome-wide genotyping of the UK Biobank was 
performed by Affymetrix using two customised microarrays, the UK 
BiLEVE and UKB Axiom arrays. Both have similar content and assay over 
800,000 genetic variants. Genotype data was imputed to a combined 
reference panel of the UK10K and 1000 Genomes Project Phase 3, using 
IMPUTE3 software. Full details on genotyping, quality control processes 
and imputation for the UK Biobank have been reported elsewhere (UK 
Biobank, 2015a, 2015b). 
Additional quality control specific to this study was performed using 
standard genetic programs PLINK2 and QCTOOL (Chang et al., 2015; 
Tool). Stringent quality filters were applied, with SNPs being retained if 
they were common (minor allele frequency ≥ 0.01), imputed with high 
certainty (INFO Score ≥ 0.9) and did not deviate substantially from Hardy-
Weinberg equilibrium (HWE p ≥ 1x10-6). Participants were retained if they 
self-identified as of European ancestry, had more than 98% of genotyped 
variants available, and exhibited a genome-wide heterozygosity within 
three standard deviations (SDs) of the cohort mean.   
7.3.5 Base datasets 
Large genome-wide association studies (GWAS) are often conducted 
through meta-analysis of various individuals cohort studies and thus, only 
summary statistics, not individual genotypes, are often available in the 
public domain.  Summary statistics from a GWAS consists of genotype 
information such as effect size, standard error and allele frequency for each 
SNP and can be used to create polygenic scores. Summary statistics from 
stage 1 of Diabetes Genetic Replication And Meta-analysis Consortium 
(DIAGRAM) version 3 was used to derive the T2DM-polygenic scores 
(Morris et al., 2012).  It comprises of 12 cohorts, with 12171 diabetes cases 
and 56862 controls (Morris et al., 2012). The cohorts consist of individuals 
of European origin, drawn from Europe, USA and Australia. Cases were 
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individuals with a clinical diagnosis of T2DM according to the American 
Diabetes Association or World Health Organization criteria.  
The latest summary statistics from the Psychiatric Genomics 
Consortium Major Depressive Disorder Phase 2 (PGC-MDD-29) study was 
used to derive the depression-polygenic scores. The PGC-MDD-29 
comprises of 29 cohorts, with 16823 depression cases and 25632 controls 
(Ripke et al., 2013). The cohorts consist of individuals of European origin, 
drawn from Europe, USA and Australia. Cases were individuals with a 
lifetime diagnosis of major depressive disorder, ascertained through 
structured clinical interview, clinician-administered checklists or review 
of medical records.  
7.3.6 Polygenic scores 
From the SNP information in genome-wide summary statistics (p-
value for association, odds ratio), polygenic risk scores were calculated 
using the software package PRSice v1.23 (Euesden et al., 2015).  In brief, 
polygenic score is the sum of trait-associated alleles across many genetic 
loci, weighted by effect sizes estimated from a base GWAS (S. M. Purcell 
et al., 2009).  T2DM and depression-polygenic scores were generated from 
DIAGRAM and PGC-MDD-29 (base datasets) respectively. SNPs that were 
in the relevant datasets and the UK Biobank dataset were retained and 
clumped to remove SNPs in strong LD, using the default options in PRSice.  
For each individual, T2DM and depression-polygenic scores were 
generated using SNPs with association p-values at seven threshold (PT< 
0.001, 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5).  
7.3.7 Statistical analysis 
7.3.7.1 Logistic regression  
Logistic regression was used to assess the association between i) 
T2DM-polygenic scores and depression case/control status and ii) 
depression-polygenic scores and T2DM case/control status. Covariates 
were included to adjust for genotyping batch, assessment centre and ten 
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ancestry-informative Principal Components (PC1-10), to address any 
potential confounding that arises from technical artefacts and population 
stratification.  
Secondary analyses included examining the effect of i) sex, ii) BMI 
and iii) severity of depression.  This is achieved by stratifying the sample 
by sex and by including an interaction term of sex and of BMI with each 
polygenic risk score.  For statistically significance findings, models were 
also adjusted for interactions between covariate of interest (namely sex or 
BMI) and i) PC1-10, ii) genotyping batch, and iii) assessment centre, in 
order to further control for confounders (Keller, 2014).  In addition, the 
association between T2DM-polygenic scores and severe depression 
case/control status was also examined.   
From each model, we extracted the proportion of variance for 
T2DM/depression status explained by the polygenic risk score 
(Nagelkerke's pseudo-R2) and the p-value for the fit of the model. Given the 
potential of multiple testing for 7 PT and 12 analyses, significance for each 
test was set at 0.0005 after Bonferroni correction (0.05/84).  This is a 
conservative significance threshold, given that SNPs at different PT are 
likely to be correlated. Post-hoc power calculations were performed in 
Additive Variance Explained and Number of Genetic Effects Method of 
Estimation (AVENGEME) (Palla & Dudbridge, 2015).  It is a statistical 
package designed for power calculations of genetic models from polygenic 
scores.  All statistical analyses were implemented in R (http://www.r-
project.org).  
7.3.7.2 LD score regression 
LD score regression is a statistical method for estimating 
heritability and genetic correlation from summary GWAS statistics (B. K. 
Bulik-Sullivan et al., 2015).  We therefore first conducted a GWAS for 
T2DM and depression in UK Biobank using the software package 
SNPTEST and then generated T2DM and depression summary statistics 
respectively.  We implemented frequentist tests on probabilistic dosage 
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estimates from the imputed genotypes (Marchini & Howie, 2010). T2DM 
and depression were then separately regressed on the covariates from the 
logistic models (sex, age, assessment centre, birth cluster, deprivation 
index, batch and top 10 PCs) and the resulting residuals were used as the 
phenotype for GWAS. 
In LD score regression, SNP-heritability for a trait is estimated by 
regressing the association statistic of a SNP on the average LD between 
the SNP of interest and proximal SNPs (the LD score). Genetic correlation 
between two traits can be estimated by regressing the product of the 
normalised association statistics for each SNP on the LD score. For this 
analysis, LD score is estimated from the European subset of the 1000 
Genomes. LD score regression accounts for both LD-independent and LD-
dependent errors and therefore avoids any bias arising from sample 
overlap (B. Bulik-Sullivan et al., 2015). This is of particular important, as 
we are estimating heritability and genetic correlation from the same 
dataset in this study. 
7.4 Results 
7.4.1 Demographics and analytical sample 
The UK Biobank sample with genotyping data consisted of 152551 
participants (80702 males; 71547 females), with a mean age of 56.6 years 
(SD: 8.0) and mean BMI of 27.6 kg/m2 (4.9; Table 7-1). Restricting to 
samples of European ancestry, there was i) 5949 cases and 137763 controls 
for T2DM and ii) 10005 cases and 19314 controls for depression. 
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Table 7-1 Demographic characteristics of individuals with genotyping 
data from UK Biobank. 
ap-values were calculated using χ2 for quantitative variables and t-test for discrete 
variables.  
7.4.2 Polygenic risk scoring 
Both T2DM and depression-polygenic scores were strongly 
predictive of their corresponding disorders. The maximum variance 
explained was 0.99% for T2DM (p<10-92 at PT<0.2) and 0.25% for 
depression (p<10-13 at PT<0.5). T2DM-polygenic scores were not predictive 
of depression case status and depression-polygenic scores were not 
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Table 7-2 Association of i) depression-polygenic scores with T2DM in UK Biobank and ii) T2DM polygenic scores with 
depression at various PT. 
 
 i) Association with T2DM  ii) Association with depression 
 Depression-polygenic scores  T2DM-polygenic scores 
 OR (95% CI) R2 explained (%) p  OR (95% CI) R2 explained (%) p 
PT        
< 0.001 1.01 (0.99-1.04) 0.0252 0.303  1.00 (0.98-1.02) 0.0007 0.695 
< 0.05 1.02 (0.99-1.05) 0.0051 0.142  1.00 (0.97-1.02) 0.0003 0.793 
< 0.1 1.01 (0.99-1.04) 0.0026 0.296  1.00 (0.97-1.03) 2.3 x 10-5 0.944 
< 0.2 1.01 (0.98-1.04) 0.0013 0.458  1.00 (0.98-1.03) 0.0009 0.658 
< 0.3 1.01 (0.98-1.04) 0.0012 0.470  1.00 (0.98-1.03) 0.0009 0.670 
< 0.4 1.01 (0.98-1.04) 0.0016 0.417  1.00 (0.97-1.03) 3.8 x 10-6 0.978 
< 0.5 1.01 (0.98-1.04) 0.0012 0.472  1.00 (0.97-1.03) 4.1 x 10-5 0.925 
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7.4.3 Secondary analysis 
All findings were statistically non-significant after Bonferroni 
correction.  Nominally significant results were observed in secondary 
analysis.  When stratified by sex, an association between depression-
polygenic scores and depression case status was observed in males only (R2 
explained=0.022%; p=0.020 at PT<0.1; Table 7-3). The interaction between 
sex and depression-polygenic scores has an effect on T2DM case-status 
(p=0.037 at PT<0.1; Table 7-4) whereas the interaction between BMI and 
T2DM-polygenic scores has an effect on depression case-status (p=0.0009 
at PT<0.001; Table 7-4).  When sex and BMI were further controlled for 
cofounders respectively, such as sex × genotyping batch, sex × assessment 
centre and sex × PC 1-10, the results remain marginally significant for i) 
sex and depression-polygenic scores on T2DM case-status (p=0.027 at 
PT<0.1; results not shown) and ii) BMI and T2DM-polygenic scores on 
depression case-status (p=0.009 at PT<0.001; results not shown).  
The interaction between sex and T2DM-polygenic scores has no 
effect on depression case-status, nor the interaction between BMI and 
depression-polygenic scores on T2DM case-status (Table 7-4). T2DM-
polygenic scores were not predictive of severe depression case-status 
(Table 7-5).   
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Table 7-3 Association of i) depression-polygenic scores with T2DM and ii) T2DM-polygenic scores with depression in UK 
Biobank, stratified by sex, at various PT. 
p-value significant at 0.05 
 i) Association with T2DM 
 Depression-polygenic scores 
 Males  
3884 cases; 63543 controls 
  Females 
2065 cases; 74220 controls 
 OR (95% CI) R2 explained (%) p  OR (95% CI) R2 explained (%) p 
PT        
< 0.001 1.01 (0.98-1.04) 0.0015 0.550  1.02 (0.97-1.06) 0.0034 0.450 
< 0.05 1.04 (1.01-1.07) 0.0212 0.024*  0.99 (0.94-1.04) 0.0011 0.668 
< 0.1 1.04 (1.01-1.07) 0.0224 0.020*  0.98 (0.93-1.02) 0.0074 0.265 
< 0.2 1.03 (0.99-1.06) 0.0104 0.113  0.98 (0.94-1.02) 0.0030 0.474 
< 0.3 1.02 (0.98-1.05) 0.0459 0.293  1.00 (0.96-1.05) 1.44 x 10-7 0.996 
< 0.4 1.01 (0.98-1.05) 0.0030 0.396  1.01 (0.96-1.05) 0.0009 0.696 
< 0.5 1.01 (0.98-1.05) 0.0022 0.472  1.01 (0.97-1.06) 0.0011 0.668 
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 ii) Association with depression 
 T2DM-polygenic scores 
 Males 
3710 cases; 10878 controls 
  Females 
6295 cases; 8436 controls 
 OR (95% CI) R2 explained (%) p  OR (95% CI) R2 explained (%) p 
PT        
< 0.001 1.00 (0.96-1.04) 5.7 x 10-6 0.981  1.01 (0.98-1.04) 0.0030 0.562 
< 0.05 1.00 (0.96-1.04) 4.1 x 10-4 0.840  1.00 (0.96-1.04) 1.2 x 10-7 0.997 
< 0.1 0.99 (0.95-1.03) 0.0011 0.743  1.01 (0.97-1.05) 0.0027 0.582 
< 0.2 1.01 (0.97-1.05) 0.0031 0.581  1.00 (0.97-1.04) 0.0004 0.838 
< 0.3 1.01 (0.97-1.05) 0.0023 0.634  1.00 (0.97-1.04) 0.0005 0.810 
< 0.4 1.01 (0.97-1.05) 0.0021 0.648  0.99 (0.96-1.03) 0.0010 0.745 
< 0.5 1.01 (0.97-1.05) 0.0029 0.592  0.99 (0.96-1.03) 0.0011 0.732 
  
131 
Table 7-4 Association of the interaction between i) sex and depression-polygenic scores with T2DM, ii) sex and T2DM-
polygenic scores with depression, iii) BMI and depression-polygenic scores with T2DM, iv) BMI and T2DM polygenic scores 
with depression in UK Biobank, at various PT. 
p-value significant at <0.05; ** p-value significant at <0.001 
 i) Association with T2DM  ii) Association with depression 
 Interaction between sex and  
depression-polygenic scores 
 Interaction between sex and  
T2DM-polygenic scores 
 β SE p  β SE p 
PT        
< 0.001 -0.0088 0.0278 0.752  -0.0052 0.0254 0.838 
< 0.05 0.0424 0.0278 0.127  0.0070 0.0254 0.784 
< 0.1 0.0578 0.0278 0.037*  -0.0018 0.0253 0.944 
< 0.2 0.0367 0.0278 0.186  0.0190 0.0253 0.454 
< 0.3 0.0119 0.0278 0.668  0.0175 0.0253 0.491 
< 0.4 0.0003 0.0278 0.992  0.0260 0.0253 0.305 
< 0.5 -0.0028 0.0278 0.921  0.0277 0.0253 0.275 
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 iii) Association with T2DM  iv) Association with depression 
 
Interaction between BMI and  
depression-polygenic scores 
  
Interaction between BMI and  
T2DM- polygenic scores 
 β SE p  β SE p 
PT        
< 0.001 -2.5 x 10-3 0.0022 0.991 < 0.001 -0.0086 0.0026 0.0009** 
< 0.05 0.0036 0.0022 0.094 < 0.05 -0.0058 0.0026 0.0267* 
< 0.1 0.0019 0.0022 0.390 < 0.1 -0.0064 0.0026 0.0148* 
< 0.2 0.0028 0.0022 0.208 < 0.2 -0.0050 0.0026 0.0579 
< 0.3 0.0021 0.0022 0.335 < 0.3 -0.0045 0.0026 0.0851 
< 0.4 0.0026 0.0022 0.233 < 0.4 -0.0037 0.0026 0.155 





Table 7-5 Association of T2DM-polygenic scores with severe depression in UK Biobank, at various PT. 
 
Association with severe depression 
Cases of severe depression: 2607; controls: 19314 
 T2DM-polygenic scores 
 R2 explained (%) p 
PT   
< 0.001 <0.0001 0.912 
< 0.05 <0.0001 0.504 
< 0.1 <0.0001 0.749 
< 0.2 <0.0001 0.655 
< 0.3 <0.0001 0.845 
< 0.4 <0.0001 0.916 





7.4.4 LD score regression 
We also estimated the genetic correlation between T2DM and 
depression using LD score regression as it is protected against bias due to 
sample overlap and population stratification.  Summary statistics for 
T2DM and depression was first created from UK Biobank.  SNP-
heritability on the liability scale was 0.20 (95% confidence interval (CI): 
0.14-0.24) for T2DM and 0.10 (95% CI: 0.06-0.15) for depression, assuming 
population prevalence of 8% and 12% for T2DM and depression 
respectively.  
The phenotypic correlation between T2DM and depression was non-
significant (r=0.03; 95% CI: 0-0.07; p=0.07).  This needs to be interpreted 
in the context of a low prevalence of T2DM in the sample (5949 T2DM 
cases; 137763 controls; 4.1% of T2DM cases) and the depression controls 
were screened for psychiatric disorders (10005 depression cases; 19314 
controls; 34.1% of depression cases).  The genetic correlation using LD 
score regression was statistically non-significant (rg=-0.08; 95% CI: -0.30-
0.14; p=0.474).  
7.4.5 Power calculation 
In post-hoc power calculation using AVENGEME, the power of 
polygenic risk scores was 41.7% between T2DM-polygenic scores and 
depression (at PT<0.2, α=0.05 and genetic correlation was assumed at 0.2 
using estimates derived from twin studies (Kan et al., 2016) and 6.3% 
between depression-polygenic scores and T2DM (at PT<0.2 and genetic 
correlation estimated at 0.2), assuming population prevalence of 8% and 
12% for T2DM and depression respectively and 5% of SNPs markers 
having an effect on T2DM/depression (Figure 7-1).  
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Figure 7-1 Power as a function of p-value thresholds for selecting SNP 
markers (PT) into i) T2DM-polygenic scores in predicting depression and 
ii) depression-polygenic scores in predicting T2DM, at various genetic 
correlation (rg) and α=0.05.  
Assumptions: population prevalence of 8% for T2DM and 12% for depression; 5% of SNPs 
markers having an effect on T2DM/depression.  
 
7.5 Discussion 
To our knowledge, this is the largest study to date that explores the 
genetic overlap between T2DM and depression, using the polygenic score 
approach at a population level.  T2DM-polygenic scores were not 
associated with depression, nor depression-polygenic scores with T2DM. 
The genetic correlation between T2DM and depression was negative and 
statistically not different from zero. Our study therefore did not support 
the hypothesis of a genetic overlap between T2DM and depression in the 
i)	T2DM-polygenic	scores	predicting	depression	in	UK	Biobank ii)	Depression-polygenic	scores	predicting	T2DM	in	UK	Biobank
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UK population. Using the LD score regression approach, we reported a 
non-significant, negative genetic correlation between T2DM and 
depression.  This is similar to the finding from a recent analysis of the 
summary statistics from DIAGRAM and an earlier version of PGC-MDD 
whereby a non-significant, positive genetic correlation for T2DM and 
depression was reported (rg (standard error (SE)): 0.051 (0.117), p=0.666) 
(B. Bulik-Sullivan et al., 2015). 
The negative finding differs from previous twin studies whereby a 
genetic overlap between T2DM and depression was observed.  A possible 
explanation for the difference is that the classic twin studies capture 
additive and non-additive effects of genetic factors across the allelic 
spectrum, but a GWAS using commercial microarrays predominantly 
captures common variants. Methods relying on GWAS data therefore do 
not directly detect the effect of uncommon variants, copy number variants, 
parental/maternal transmission and epistasis.  This is in part reflected in 
the difference between the variance explained by GWAS SNPs (SNP-
heritability) and heritability estimates from twin studies for T2DM and 
depression.  For example, the heritability for depression is estimated to be 
37% in twin studies (Flint & Kendler, 2014) whereas it is 14% from the 
latest PGC-MDD-29 (Ripke et al., 2013).  Our findings should therefore be 
interpreted in the context of this missing heritability, although a recent 
study has suggested that low frequency and rare variants are unlikely to 
be an important source of contribution to the heritability of T2DM in 
comparison to common variants (Fuchsberger et al., 2016).   
With recent advances in whole-genome sequencing technologies, the 
proportion of genetic variation captured by genotyped data should 
eventually be closer to ones from twin studies (Yang et al., 2015). The 
genetic correlations between T2DM and depression observed from twin 
studies might reflect the upper bounds of the variance in liability 
attributable to genetic factors, since heritability estimates derived from 
twin studies are consistently higher than those from GWAS (Manolio et 
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al., 2009).  In addition, the equal environment assumption whereby MZ 
and DZ twins are correlated for shared environmental influences to the 
same extent has been challenged.   Prenatal development process might 
lead MZ twins being epigenetically more similar than DZ twins, potentially 
overestimating the heritability component (Golan et al., 2014).  Further 
research is needed to clarify this hypothesis and its effect.    
It is also possible that the observed co-heritability between T2DM 
and depression in twin studies is attributable to aetiological diversity, with 
a subset of individuals with one disease being genetically similar to 
individuals with another disease (Wray, Lee, & Kendler, 2012). For 
example, a recent study with 3230 participants from the Netherlands 
Study of Depression and Anxiety and Netherlands Twin Registry has 
reported a genetic overlap between BMI and atypical depression, but not 
typical depression, defined as changes in appetite/weight (Milaneschi et 
al., 2015).  Of note, the twin studies reporting significant genetic overlap 
between T2DM and depression utilise their respective national hospital 
discharge registries in their case definition for T2DM and depression (Kan 
et al., 2016). These do not include visits to general practitioners and its 
authors therefore noted that it might capture more severe cases. In our 
study, T2DM-polygenic scores were not predictive of depression case status 
when case status is restricted to individuals with severe depression. The 
sample size is, however, reduced substantially (cases: 2607; controls: 
19314). 
Our secondary analysis suggests that sex might play a role in the 
effect of depression-polygenic scores on T2DM case status, and BMI with 
T2DM-polygenic scores on depression case-status. The results were not 
statistically significant after multiple testing corrections. These findings 
need to be interpreted with caution since it is possible that a proportion of 
individuals in the base dataset (DIAGRAM) is also in the target dataset 
(UK Biobank).  We were able to ascertain this possibility for depression 
but not for T2DM, as we only have access to the summary statistics of 
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DIAGRAM.  The likely effect of sample overlap between base and target 
datasets is inflation in variance explained and might therefore explain the 
spurious association of the interaction between BMI and T2DM-polygenic 
scores on depression case-status in the secondary analysis.  Replication of 
our finding in an independent dataset will address sample overlap between 
base and target datasets. Within the limits of our methodology, it is 
currently not possible to conclude the significance of the effect observed in 
our data.   
7.5.1 Limitation 
Both T2DM and depression-polygenic scores show statistically 
significant predictive ability for their respective disorders in UK Biobank, 
but they only explain a small amount of the phenotypic variance observed 
(T2DM: 0.99%; depression: 0.25%). This is reflected in limited power of 
association testing between T2DM and depression-polygenic scores 
(41.7%) and depression and T2DM-polygenic scores (6.3%).  Our study is 
well powered for examining the genetic overlap between T2DM and 
depression if the genetic correlation between T2DM and depression is ~0.4 
(power=93.9% at PT<0.2 and α=0.05).   
Given the sex-specific genetic correlations reported from twin 
studies are ~0.2, our study is under powered despite utilising the largest 
population cohort for T2DM and depression to date. Future meta-analysis 
on the genetic overlap between T2DM and depression in large population 
cohorts and utilising larger base datasets to generate polygenic scores 
could potentially address the pitfall of type-II errors. 
A further limitation is the reliance on self-reported data for 
identifying individuals with T2DM and depression. Some misclassification 
of diabetes status could have occurred, but this is likely to be moderate, 
given T2DM covers 90% of adults with diabetes (Alberti & Zimmet, 1998). 
The UK Biobank has recently collected additional data on depressive 
symptoms, using the Composite International Diagnostic Interview Short 
Form (Kessler, Andrews, Mroczek, Ustun, & Wittchen, 1998).  It should be 
139 
available in early spring 2017, allowing us to examine the genetic overlap 
between T2DM and specific depressive symptom. More accurate 
phenotyping, such as the use of repeated measures and semi-structured 
interviews, could potentially improve the heritability estimates for T2DM 
and depression.  
7.6 Conclusion  
Both T2DM and depression are likely due to a combination of 
genetic and environmental factors.  The current study is unparalleled in 
its sample size for polygenic score analysis. Our finding of no genetic 
overlap between T2DM and depression contrasts with the positive findings 
from twin studies (Kan et al., 2016).  Further work is needed to understand 
the reasons underling the discrepancy in findings, allowing better 
understanding of pathogenesis underlying both disorders. 
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Chapter 8  




But as, in ethics, evil is a consequence of good, so, in fact, out of joy is sorrow 
born. Either the memory of past bliss is the anguish of today, or the agonies 
which are have their origin in the ecstasies which might have been.”  
~ Edgar Allan Poe, Berenice  	 	
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The association between type 2 diabetes (T2DM) and depression has 
been consistently reported in epidemiological studies.  The T2DM-
depression link may be symptom-specific.  We therefore examined whether 
polygenic risk scores for T2DM predict specific depressive symptoms in the 
Psychiatric Genomics Consortium Major Depressive Disorder Phase 2 
(PGC-MDD-29). 
8.1.2 Method  
T2DM-polygenic scores were constructed from the association 
summary statistics of Diabetes Genetic Replication And Meta-analysis 
Consortium (DIAGRAM; 12171 cases and 56862 controls), at seven 
association p-value thresholds (PT<0.0001-0.5). Stepwise regression was 
used to test for association between T2DM-polygenic scores at PT<0.5 and 
specific depressive symptoms in PGC-MDD-29 (2360 cases and 4182 
controls), adjusting for principal components (PCs) and study. Secondary 
analyses involved stratification by depression case-control status and sex.   
8.1.3 Results 
Feelings of guilt/worthlessness is the only significant depressive 
symptom predictor for T2DM-polygenic scores at PT<0.5 (β=-0.00004; 
p=0.0037).  The association remains significant for T2DM-polygenic scores 
between PT<0.1 and PT<0.4.  When stratified by depression case-control 
status and sex, feelings of guilt/worthlessness is the only significant 
depressive symptom predictor for T2DM-polygenic scores at PT<0.5 in 
depression cases (p=0.0003).  
8.1.4 Conclusion 
This study provides the first evidence of a shared genetic aetiology 
between T2DM and feelings of guilt/worthlessness, particularly in people 
with depression.  Our finding tentatively supports that the epidemiological 
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association between T2DM and depression might have a genetic 
underpinning.  
8.2 Background 
Both T2DM and depression are common global disorders, with 
depression being associated with both insulin resistance (Kan et al., 2013)  
and T2DM (Golden et al., 2008).  Individuals with depression have worse 
glycaemic control, greater diabetes complications and higher rates of 
mortality (Black, Markides, & Ray, 2003; Lustman et al., 2000).  
Treatment of depression does not always lead to improvement in glycaemic 
control (Markowitz, Gonzalez, Wilkinson, & Safren, 2011).  There is 
accumulating evidences that substantial heterogeneity exists in the 
psychopathology of depression (Harald & Gordon, 2012). Data-driven 
approaches have reported the existence of symptoms-based subtypes, 
namely atypical and typical depression (Alexandrino-Silva et al., 2013; 
Lamers et al., 2013; Li et al., 2014).  The former is often characterised by 
the presence of increased appetite/weight and/or hypersomnia and is 
associated with adiposity measures, such as body mass index (BMI), waist 
circumference and incidence of obesity (Lasserre et al., 2014).  Given 
visceral obesity has been postulated as a biological explanatory link for the 
T2DM-depression association (Champaneri et al., 2010; Golden et al., 
2008), certain depressive subtypes might be associated with T2DM, 
suggesting the existence of a subset of individuals with common 
pathophysiology.  
Inflammation has also been reported to be involved in the 
pathogenesis of the T2DM-depression link, with inflammatory markers, 
such as C-Reactive Proteins, being associated with depressive symptoms 
in individuals with newly diagnosed T2DM (Laake et al., 2014).  Of 
interest, association between inflammatory biomarkers and depression 
has been suggested to be symptom-specific.  For example, a recent study 
reported that elevated levels of CRP are associated with specific depressive 
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symptoms, namely change in appetite, sleep disturbances and fatigue in 
the general population (Jokela, Virtanen, Batty, & Kivimaki, 2016). 
Twin studies have suggested qualitative and quantitative sex 
differences in the shared genetic aetiology between T2DM and depression 
(Kan et al., 2016) but no genetic overlap has been observed in GWAS 
datasets using polygenic scores and LD score regression approaches (B. 
Bulik-Sullivan et al., 2015; Clarke et al., 2015; Samaan et al., 2015).  The 
underlying genetic aetiology between T2DM and depression is currently 
unclear.  Previous research examining T2DM and depression has, 
however, assumed depression is a homogeneous condition.  Given the large 
phenotypic and aetiological heterogeneity of depression and variation in 
response to treatment of depression, it might be useful to examine whether 
there is a genetic overlap between T2DM and specific depressive 
symptoms, rather than studying depression as a whole.  The value of 
studying depression subtypes in understanding the genetic overlap with 
physical disorders was seen in a recent study with 3230 participants from 
the Netherlands Study of Depression and Anxiety and Netherlands Twin 
Registry (Milaneschi et al., 2015). It reported a genetic overlap between 
BMI-polygenic scores and atypical depression, defined as increased 
appetite/weight (Milaneschi et al., 2015). In this study, we aim to 
determine whether there is an association between T2DM-polygenic scores 
and specific depressive symptoms in PGC-MDD-29.  
8.3 Methods 
8.3.1 Sample 
The PGC-MDD is an on-going international collaboration with the 
aim of understanding the genetics architecture of major depressive 
disorder.  The latest dataset consists of 29 research studies, with 16823 
depression cases and 25632 controls (Ripke et al., 2013). In brief, it 
comprises individuals of European descents from Europe, USA and 
Australia. Cases were individuals with a lifetime diagnosis of major 
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depressive disorder as defined in the Diagnostic and Statistical Manual of 
Mental Disorder-4th Edition (DSM-IV).  Diagnostic information was 
ascertained through structured clinical interview, clinician-administered 
checklists or review of medical records.   Controls were mainly selected 
from the population and screened for lifetime depression.  Cohorts included 
in both stage 1 of DIAGRAM and in PGC-MDD-29 were excluded from 
analysis.   In addition, we excluded any cohort whereby depressive 
symptoms were available for depression cases or controls only or have less 
than 50 individuals providing information on specific depressive 
symptoms.  This led to a total of 4 cohorts, with 2360 cases and 4182 
controls with sufficient information on genotype and depressive symptoms 
for analysis.  
8.3.2 Depressive symptoms 
Depressive symptoms were defined according to Diagnostic and 
DSM 4th Edition as followed: i) low mood, ii) anhedonia (a loss of interest 
or pleasure in daily activities), iii) changes in appetite/weight, iv) sleep 
disturbances, v) psychomotor disturbances, vi) fatigue, vii) feelings of 
guilt/worthlessness, viii) poor concentration and ix) suicidality.  All 
symptoms were defined as either “absent” or “present”, including 
symptoms with bidirectional response, namely: i) changes in 
appetite/weight, ii) sleep disturbances and iii) psychomotor disturbances.  
They were defined as “absent” or “changes in either direction”.  
8.3.3 Genotyping and imputation 
The quality control procedures adopted in PGC-MDD-29 analysis 
are applied to all PGC studies, and have been described in details 
elsewhere (Ripke et al., 2013).  In brief, the PGC designed the “Ricopili” 
pipeline (https://github.com/Nealelab/ricopili/wiki) to process all 
individual-level genotype data.  It is used for quality control, imputation 
and analysis of genotype data, ensuring uniform procedures across all 
cohorts. Empirical relatedness was computed from genotype data and one 
of each duplicated/related pair, defined as π>0.2, was excluded.  The 
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quality control applied per cohort included: i) minor allele frequency ≥ 0.01, 
ii) Hardy-Weinberg equilibrium p ≥ 0.0001 and iii) imputation marker 
information content metric (INFO) score ≥ 0.6.  For imputation, the 1000 
Genomes Project multi-ancestry reference panel was used (Abecasis et al., 
2010).   Ancestry informative PCs were calculated for each study in PGC-
MDD-29, allowing us to control for the effect of population stratification in 
statistical analysis.  Imputed data converted to hard-called genotypes was 
used to build the T2DM-polygneic scores.   
8.3.4 Base dataset 
T2DM-polygenic scores are created from the summary statistics 
from stage 1 of DIAGRAM version 3 (Morris et al., 2012).  It comprises of 
12 cohorts, with 12171 diabetes cases and 56862 controls (Morris et al., 
2012). The cohorts consist of individuals of European descents from 
Europe, USA and Australia. Cases were individuals with a clinical 
diagnosis of T2DM according to the American Diabetes Association or 
World Health Organization criteria.  
8.3.5 Polygenic scores 
T2DM-polygenic risk scores were calculated using the software 
package PRSice v1.23 (Euesden et al., 2015).  In brief, polygenic score is 
the sum of trait-associated alleles across many genetic loci, weighted by 
effect sizes estimated from a base GWAS (S. M. Purcell et al., 2009). T2DM-
polygenic scores were generated from Stage 1 of DIAGRAM version 3 (base 
dataset). SNPs that were in both DIAGRAM and PGC-MDD-29 were 
retained and clumped to remove SNPs in strong LD, using the default 
options in PRSice. For each individual in PGC-MDD-29, T2DM-polygenic 
scores were generated using SNPs with 7 PT (<0.001, 0.01, 0.1, 0.2, 0.3, 0.4 
and 0.5).  
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8.4 Statistical analysis  
To assess the level of correlation between depressive symptoms, we 
first calculated tetrachoric correlations between the symptoms.  We then 
used Principal component analysis (PCA) to dissect and capture the 
underlying structure between depressive symptoms.  PCA is a statistical 
method that reduces a set of possibly correlated variables into linearly 
uncorrelated variables called PCs (Jolliffe, 2002). It therefore reduces 
dimensionality of a dataset while retaining most of its variation (Ringner, 
2008).  The number of PCs retained for further analysis was determined 
according to Kaiser criterion (Kaiser, 1960), whereby PCs with eigenvalues 
≥1 were retained.   
It should, however, be noted that PCA is not designed to identify 
directions for separating classes of samples.  Biplot is often used to 
visualised the results from PCA.  It extends the idea of a simple scatterplot 
of two variables to multiple variables, allowing maximum visualisation of 
information in a dataset.  In a biplot, the rows and columns of the target 
matrix are visualized by their scalar product (Greenacre & Primicerio, 
2013).  Scatterplots and biplot of the first and second PC were plotted to 
identify potential sources of data variation, such as i) depression case-
control status, ii) sex, iii) study and iv) specific depressive symptoms. 
Stepwise linear regression was then used to assess the association 
between T2DM-polygenic scores and nine depressive symptoms as 
described under “depressive symptoms”.  The outcome of interest is T2DM-
polygenic scores at PT<0.5.  We built a model by successively adding or 
removing explanatory variables, namely specific depressive symptoms, 
based on the Akaike information criterion, allowing us to fine-tune the 
model.  The first six ancestry-informative PCs from the PGC-MDD 29 
meta-analysis, PCs retained from the depressive symptoms PCA analysis 
and an indicator for each study were included as covariates, in order to 
address any potential confounding that arises from population 
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stratification and study artefacts (results not reported for these 
explanatory variables).  A predictor is considered statistically significant 
for the stepwise linear regression if p-value is <0.01.    
The best fitting model was then tested with T2DM-polygenic scores 
at the remaining 6 PT (< 0.001, 0.01, 0.1, 0.2, 0.3 and 0.4).  For each model, 
we extracted the standardised regression coefficients (β), the proportion of 
variance in T2DM-polygenic scores explained (Nagelkerke's pseudo-R2) 
and the p-value for each explanatory variable. Secondary analyses 
included examining the effect of depression case-status and sex by sample 
stratification.  All statistical analyses were implemented in R 
(http://www.r-project.org).  
8.5 Results  
8.5.1 Descriptive analysis 
The four cohorts from PGC-MDD-29 included in this study were: i) 
CoFaMS (Air, Weightman, & Baune, 2015), ii) PsyCoLaus (Preisig et al., 
2009), iii) NESDA  (Penninx et al., 2008) and iv) SHP0 (Volzke et al., 2011).  
In brief, CoFaMS is a case-control study and participants were recruited 
from the general community and clinical services in Australia, with 
depressive symptoms assessed by Mini Neuropsychiatric Diagnostic 
Interview 6.0 (Sheehan et al., 1998) and Hamilton Depression and Anxiety 
Scales (Williams, 1988).  PsyCoLaus is a population-based study and 
participants were recruited from the population registry in Switzerland, 
with depressive symptoms assessed by Diagnostic Interview for Genetic 
Studies (Nurnberger et al., 1994) with additional questions added to elicit 
atypical depression features.  NESDA is a naturalistic, longitudinal cohort 
study and participants were recruited from various health care settings, 
ranging from community to specialised mental health care in The 
Netherlands, with depressive symptoms assessed by Composite Interview 
Diagnostic Instrument (Wittchen, 1994) and Inventory of Depressive 
Symptoms (Rush et al., 1996).  SHP0 is a population-based project and 
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participants were recruited from the residence registries in Germany, with 
depressive symptoms assessed by Mini-Mental Test (Folstein, Folstein, & 
McHugh, 1975). 
In total, these consisted of 6542 participants (2838 males; 3704 
females) of European ancestry, with a mean age at interview of 46.7 years 
(SD: 14.3; Table 8-1).  There were 2360 cases and 4182 controls for 
depression.  The number of individuals with response for each depressive 
symptom is summarised in table 2.  Substantial tetrachoric correlations 
exist between the depressive symptoms (Figure 8-1).   
 
Table 8-1 Demographic characteristics by study in PGC-MDD-29. 











































Table 8-2 Depressive symptoms of individuals by study in PGC-MDD-29. 
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Figure 8-1 Tetrachoric phenotypic correlation matrix across depressive 
symptoms in PGC-MDD-29. 
Colour of each box indicates the magnitude of the correlation, size of the boxes indicates its 
significance.   
 
8.5.2 PCA analysis of depressive symptoms 
The first PC explains 71.9% of the original variance in the nine 
depressive symptoms whereas the second PC explains 6.3% of the 
variance.  The first PC is the only PC with eigenvalues ≥1 and is therefore 
retained for further analysis (Figure 8-2).  
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Figure 8-2 Proportion of variance fit by each PC in PGC-MDD-29. 
 
Visual inspection of the scatterplots suggests that a potential source 
of data variation for PC1 was depression case-control status while sex and 
study did not explain much of the data variation for PC2 (Figure 8-3).  In 
the biplot of PC1 verses PC2, the points represent depressive symptoms 
and points which cluster together have similar profiles on the PCs (Figure 
8-4).   The biplot suggests that a potential source of data variation for PC2 
is suicidality and the remaining 8 depressive symptoms.  Linear regression 
demonstrates that 75.6% of the variation in PC1 was accounted by 
depression case-control status whereas 83.8% of the variation in PC2 was 
accounted by suicidality. 
153 
Figure 8-3 Scatterplots of PCA in PGC-MDD-29.   
Datasets are colour coded to show the inherent clustering of datasets by i) depression 





Figure 8-4 Biplots of PCA in PGC-MDD-29.   
Datasets are colour coded to show the inherent clustering of datasets by depressive 
symptoms; MDD1: low mood; MDD2: anhedonia; MDD3: changes in appetite/weight; 
MDD4: sleep disturbances; MDD5: psychomotor disturbances; MDD6: fatigue; MDD7: 
feelings of guilt/worthlessness; MDD8: poor concentration and MDD9: suicidality. 
 
8.5.3 Stepwise regression 
From a full model with all symptoms of depression and PC1 as 
above, feelings of guilt/worthlessness is the only significant depressive 
symptom predictor for T2DM-polygenic scores at PT<0.5 (β=-0.00004; 
p=0.0037; Table 8-3).  Feelings of guilt/worthlessness explained only a 
small amount of the variance in T2DM-polygenic scores at PT<0.5 
(R2=0.0006%).  The association remains significant for T2DM-polygenic 
scores between PT<0.1 and PT<0.4, when the PC1-6 from the PGC-MDD 29 
meta-analysis, PC1 from the depressive symptoms PCA analysis and an 
indicator for each study were included as covariates (Table 8-4).  Again, 
the amounts of variance in T2DM-polygenic scores explained by feelings of 
guilt/worthlessness is very small (R2: 0.0006%~0.002%). 
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Table 8-3 Best-fitting model for T2DM polygenic scores at PT<0.5 with 
depressive symptoms in PGC-MDD-29. 
b: standardised regression coefficients, * p-value significant at 0.01 
Table 8-4 Association T2DM-polygenic scores and feelings of 
guilt/worthlessness at various PT in PGC-MDD-29. 
b: standardised regression coefficients; p-value significant at 0.01 
Explanatory factors b p 
PsyCoLaus 0.889 <0.0001* 
NESDA 1.694 <0.0001* 
SHP0 1.752 <0.0001* 
PC1 from depressive symptoms -0.003 0.1392 
Psychomotor disturbances 0.002 0.0868 
Feelings of guilt/worthlessness -0.004 0.0037* 
PT b R2 explained (%) p 
<0.0001 0.019 0.0107 0.3712 
<0.001 -0.029 0.0247 0.1665 
<0.01 -0.020 0.0120 0.0508 
<0.1 -0.008 0.0020 0.0054* 
<0.2 -0.006 0.0011 0.0051* 
<0.3 -0.005 0.0008 0.0017* 
<0.4 -0.005 0.0007 0.0016* 
<0.5 -0.004 0.0006 0.0016* 
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8.5.4 Secondary analysis 
The stepwise regression was repeated with the sample stratified by 
i) depression case-control status and ii) sex.   T2DM-polygenic scores at 
PT<0.5 is the outcome of interest.  For depression cases, feelings of 
guilt/worthlessness is the only significant depressive symptom predictor 
for T2DM-polygenic scores (β=-0.00005; p=0.0003; results not shown).  For 
depression controls or males or females, no association between depressive 
symptom and T2DM-polygenic scores was observed.  
8.6 Discussion 
To our knowledge, this is the first study to examine the association 
between T2DM-polygenic scores and specific depressive symptoms.  Our 
finding suggests that a small, negative but statistically significant 
association between T2DM-polygenic scores and feelings of 
guilt/worthlessness, particularly in people with depression.  Our finding 
might appear surprising, given there is no genetic overlap between T2DM 
and depressive symptoms commonly associated with anthropometric 
measures, namely changes in appetite/weight, sleep disturbances and 
fatigue (Twist et al., 2013).  
The absence of feelings of guilt/worthlessness might be the 
mechanism by which a genetic propensity for T2DM exerts its influence on 
depression, as guilt is a key affective component of conscientiousness 
(Fayard, Roberts, Robins, & Watson, 2012).  Conscientiousness-related 
traits have been showed to be a predictor of lower BMI (Hampson, 
Goldberg, Vogt, & Dubanoski, 2007) and BMI is a well-recognised risk 
factor for T2DM and depression respectively (Kodama et al., 2012; Simon 
et al., 2006).  In people with T2DM, those with high scores for 
conscientiousness exhibit greater desirable diabetes self-care behaviours 
than their less conscientious counterparts (Skinner, Bruce, Davis, & Davis, 
2014).  In people with depression, unhealthy lifestyle-related behaviours, 
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such as smoking, physical inactivity and poor diet, have been suggested to 
be risk factors for developing T2DM (Renn et al., 2011).  
Our finding is best illustrated if we examine the following two 
clinical scenarios.  Individuals A and B have a genetic propensity to T2DM 
and both develop T2DM.  Individual A might feel less responsible for being 
diagnosed with T2DM and is therefore less conscientious about diabetes 
management.  In contrast, the feelings of guilt/worthlessness might 
motivate behavioural changes in individual B.   As a result, worse 
glycaemic control might place individual A at a higher risk of developing 
depression than individual B, given the reciprocal association between 
glycaemic control and depression (Schmitz, Deschenes, Burns, & Smith, 
2016).  This might explain our finding of a negative association between 
T2DM-polygenic scores and the feelings of guilt/worthlessness.  On the 
other hand, if both individuals develop depression instead of T2DM, an 
absence of feelings of guilt/worthlessness in individual A might lead to 
poorer compliance with lifestyle recommendations for depression. For 
example, overeating might be a mechanism maladapted by individual A to 
mitigate negative affect, especially in the context of obesity.   This, in turn, 
might have a greater impact on individual A in developing T2DM in 
comparison to individual B, explaining our finding of a negative 
association between T2DM-polygenic scores and feelings of 
guilt/worthlessness in depression cases, but not in controls (Figure 8-5).
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Figure 8-5 A theoretical model of the T2DM-depression association, mediated by feelings of guilt/worthlessness, for individual 
A and B. 
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Our study suggests certain depressive symptoms might be 
associated with T2DM, suggesting a depression subtype.  The current 
diagnostic criteria for depression aim to portrait it as a homogeneous 
entity.  It might, however, be comprised of multiple heterogeneous 
phenotypes and present differently in individuals with comorbid medical 
disorders, such as T2DM.  Unrevealing the phenotypic heterogeneity of 
depression might help the psychiatric field to move forward in the search 
for its molecular signature.  
Replication of our finding is needed before a more robust conclusion 
can be drawn. The UK Biobank has collected additional data on depressive 
symptoms, using the Composite International Diagnostic Interview Short 
Form (Kessler et al., 1998).  It should be available in early spring 2017, 
allowing us to validate our hypothesis and to explore the effect of residual 
covariates, such as BMI, on the T2DM-depression association.  It will also 
be of interest to examine the genetic overlap between T2DM and number 
and/or severity of depressive symptoms, allowing us to approach 
depression from a dimensional perspective.  In addition, prospective 
studies addressing the role of guilt in the T2DM and depression association 
will help to clarify our finding.  A potential implication of our finding for 
clinicians is the need to consider how a patient’s view of their responsibility 
with T2DM can have an impact on their diabetes self-management.  
Adopting therapeutic approaches with a personality modification focus 
might be beneficial in improving diabetes self-care.    
8.6.1 Limitation  
One major limitation of our study is the method of which we define 
depressive symptoms with bidirectional response.  In this study, 
depressive symptoms were defined as “absent” or “changes in either 
direction” which fails to capture the bidirectional nature of those 
symptoms.  Defining those symptoms into four groups (“absence”, 
“increase”, and both directions “and “reduce”) would lead to a substantial 
reduction in the number of individuals per group, limiting the power of our 
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study.   We therefore were unable to subdivide the depressive symptoms 
due to the nature of the information available.  This is a major limitation 
for our study since there is now accumulating evidence of a link between 
depression and immuno-metabolic dysregulations, with the association 
being stronger for depressive symptoms being in a specific direction, such 
as increased appetite/weight and hypersomnia (Cizza et al., 2012; Lamers 
et al., 2013; Rudolf, Greggersen, Kahl, Hüppe, & Schweiger, 2014).  Thus, 
the bi-directional natures of specific depressive symptoms, namely i) 
increased/reduced appetite/weight, ii) hypersomnia/insomnia, and iii) 
psychomotor agitation/retardation, are not captured in this study and their 
association with T2DM-polyugnic scores need to be further explored.  
Defining a phenotype is a challenge for large-scale, international 
consortiums, since they are often consisted of various cohorts which use 
using different diagnostic tools.  It can therefore be difficult to combine 
information at symptoms levels which are compatible across cohorts, 
leading to some compromise on the quality of the phenotype information. 
A further limitation of the study is the collinearity of the depressive 
symptoms and inherent heterogeneity of the studies included.  We have 
aimed to address this limitation by including study indicators, ancestry 
informative PCs from the PGC-MDD meta-analysis and depression PCA 
analysis as covariates in the stepwise regression.   A possible way to 
address both limitations is to re-examine our findings in a larger 
population-based cohort, such as the UK Biobank when specific depressive 
symptoms become available. In addition, association also does not imply 
causation and cross sectional data is used in this study.  This is further 
complicated by the possibility that a subgroup of patients fluctuates 
between different depressive symptoms. Repeated assessments of 
depressive symptoms and use of multiple sources would allow a more 
robust conclusion to be drawn.  In addition, objective measures that 
further explore the feelings of guilt/worthlessness are needed.  For 
example, guilt can be contextual, such as exaggerated responsibility for 
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uncontrollable events, or generalised, such as “free-floating” guilt which is 
removed from specific contexts. 
8.7 Conclusion 
This is the first study to demonstrate a genetic overlap between 
T2DM and specific depressive symptoms using the polygenic scores 
approach.  Our finding should be interpreted in the context of a small but 
statistically significant association.  The underlying genetic architecture 
of the T2DM-depression association remains largely unknown.  Our 
findings suggest that the discrepancy in finding between twin studies and 
GWAS datasets using polygenic score approach might be attributable to 
the phenotypic heterogeneity of depression, with biologically different 
subtypes.  A better understanding of the mechanisms underlying the 
T2DM-depression association is of high clinical and scientific relevance. 
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“Sorrow comes in great waves ... but rolls over us, and though it may almost 
smother us, it leaves us. And we know that if it is strong, we are stronger, 
in a smuch as it passes and we remain.”  




The aim of this thesis was to examine whether there is a genetic 
overlap between type 2 diabetes (T2DM) and depression using three 
complimentary methodologies.  In this final chapter, I will first briefly 
summarise the main findings from the three approaches, followed by an 
examination of the reasons underlying the discrepancies of the findings, 
and a conclusion in which future research is discussed. 
9.2 Summary of findings  
The three complimentary methodologies, namely structural 
equation modelling in twin datasets, polygenic scores analysis and linkage 
disequilibrium (LD) score regression in genome-wide association studies 
(GWAS) datasets are described in detail in chapters 2 and 5.  In chapter 3, 
I explored the genetic overlap between T2DM and depression in two large 
population-based Scandinavia twin datasets.  I found the phenotypic 
correlation between T2DM and depression was significant in both sexes.  
In the Swedish sample, this association was primarily attributed to unique 
environmental effects in males, and genetic effects in females. In the 
Danish sample, genetic effects accounted for the majority of the covariance 
in both sexes.  In addition, qualitative genetic sex differences are observed 
in both samples, suggesting different genetic factors are involved across 
the sexes in explaining the comorbidity.  In chapter 4, I examined whether 
our findings in the Swedish and Danish samples could be generalized to a 
non-Western population.  In the Colombo Twin and Singleton Study-Phase 
2 (COTASS-2) sample, the phenotypic correlation between depression and 
T2DM was significant in females only, and this was mainly due to 
correlated genetic factors. No qualitative sex differences were observed, 
suggesting while the same genetic and environmental factors are involved 
across the sexes, the magnitude of their effect is modulated by sex 
(quantitative sex differences).   
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My next focus was on using GWAS datasets to study the 
relationship between T2DM and depression, as consistency of a finding 
across different sample populations and methodologies will allow a more 
robust conclusion to be drawn.  In chapter 6, I conducted an exploratory 
study of the association between i) genetic susceptibility to T2DM and 
depression case-status and ii) genetic susceptibility to depression and 
T2DM case-status in the deCODE sample, using polygenic score analysis. 
T2DM-polygenic scores were not predictive of depression case-status and 
depression-polygenic scores were not predictive of T2DM case-status. In 
chapter 7, I evaluated the genetic overlap between T2DM and depression 
using polygenic score analysis and LD score regression in the UK Biobank 
sample.  I also examined the effect of sex, body mass index (BMI) and 
severity of depression on the comorbidity.  None of the findings were 
statistically significant after multi-testing correction.  In chapter 8, I 
investigated the shared genetic aetiology between T2DM-polygenic scores 
and specific depressive symptoms in PGC-MDD-29A small, negative but 
statistically significant association was observed between T2DM-polygenic 
scores and the feelings of guilt/worthlessness, particularly in people with 
depression.    
In summary, twin studies reported a genetic overlap between T2DM 
and depression in both Western (chapter 3) and non-Western (chapter 4) 
populations.  No genetic overlap was observed between T2DM and 
depression in GWAS datasets using both the polygenic score (chapter 6 
and 7) and LD score approaches (chapter 7). Feelings of 
guilt/worthlessness is the only significant depressive symptom predictor 
for T2DM-polygenic scores (chapter 8). Our results suggest that although 
depression is a correlate for T2DM and vice versa as observed in 
epidemiology studies, there is currently only limited evidence for a shared 
common genetic effect.  Our findings are summarised diagrammatically in 
Figure 9-1.    
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Figure 9-1 Summary of findings on the genetic overlap between T2DM 
and depression by PhD chapters. 
Rg: genetic correlation between T2DM and depression from twin studies; rg: genetic 
correlation between T2DM and depression from LD score regression; PGS: polygenic scores  
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9.3 The discrepancy in findings between twin 
studies and GWAS – considerations and critiques  
Our findings from twin studies imply that genetic effects are an 
important contributor in the T2DM-depression comorbidity.  It has been 
observed in females across three studies, and in males in one study.  This 
result was not replicated in three GWAS datasets, but the limited power 
of GWAS in examining the genetic overlap between T2DM and depression 
needs to be taken into account.  The UK Biobank is the largest GWAS 
dataset of T2DM and depression to date using the polygenic score 
approach.  My calculations demonstrated that this sample is only powered 
for detecting a genetic correlation between T2DM and depression of ~0.4 
(chapter 7).  A study which uses the LD score regression approach to 
estimate 276 genetic correlations among 24 traits from GWA-summary 
statistics reported a genetic correlation of 0.51 (standard error (SE): 0.08) 
between depression and schizophrenia and 0.22 (SE: 0.12) for depression 
and ulcerative colitis (1).  Genetic correlations between T2DM and 
depression derived from GWAS are unlikely to be of the magnitude of ~0.4.  
From our twin studies, we reported genetic correlations of ~0.2 in both the 
Swedish and Danish samples.   The genetic correlations derived from 
COTASS-2 are of a much higher magnitude; 0.37 (95% CI: -0.21-0.93) for 
males and 0.52 (95% CI: 0.19-0.98) respectively, but the confidence 
intervals are very wide.  The limited power of the polygenic score analysis 
is likely to explain in part of our negative findings from the GWAS 
datasets. 
9.3.1 Missing co-heritability 
The genetic covariance we observed from twin studies are likely to 
reflect the upper bound of the variance in liability attributable to genetic 
factors, given that heritability estimates derived from GWAS and Genome-
wide Complex Trait Analysis (GCTA) studies are consistently lower than 
those from twin studies.  The difference has been termed “missing 
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heritability” (Manolio et al., 2009) and various possible explanations have 
been postulated to explain this observation including rare variants (Zuk et 
al., 2014), epigenetics (Furrow et al., 2011) and gene-environment 
interactions (Kaprio, 2012).  It is possible “missing heritability” within 
traits will also lead to “missing bivariate heritability” or “missing co-
heritability”. Most complex traits are considered to be polygenic in nature, 
with multiple common genetic variants having a small effect size.   It is 
theoretically possible copy-number variations, low frequency and rare 
variants could explain the genetic architecture of T2DM and depression.  
This is known as the common disease-rare variant hypothesis (Bodmer & 
Bonilla, 2008).  For T2DM, a recent simulation study has suggested low 
frequency and rare variants are unlikely to be an important source of 
contribution to the heritability of T2DM compared to common variants 
(Fuchsberger et al., 2016).  For depression, a rare missense Asn396Ser 
mutation in the endothelial lipase gene has recently been implicated in the 
pathogenesis of depressive symptoms in a large population-based cohort 
(Amin et al., 2016).  Thus, the role which low frequency and rare variants 
might play in the T2DM-depression association remains to be determined.  
Whole genome sequencing would help to answer this question by 
identifying rare variants and capturing a few additional common variants, 
but would not entirely solve the problem.  In addition, rare variants are 
present in the population between 1% and 10% and thus, despite their 
relatively large effect sizes, the expected effect on population risks is likely 
to be low (Blanco-Gomez et al., 2016).  
It should also be noted heritability estimates derived from GWAS is 
in the narrow sense, based on the assumption that there is no interaction 
between alleles and thus, their genetic effects are entirely additive.  This 
assumption might not, however, be justified as research has demonstrated 
models with genetic interactions (epistasis) can also account for empirical 
data for medical disorders such as Crohn’s disease (Zuk, Hechter, Sunyaev, 
& Lander, 2012).  Epistasis between the genetic variants already identified 
from GWAS could therefore potentially in part explain the “missing 
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heritability“ phenomenon (Zuk et al., 2012).  Examining the extent of 
epistasis in human population studies is, however, difficult and requires 
large samples (Blanco-Gomez et al., 2016). 
Another hypothesis proposed to explain the “missing co-heritability” 
conundrum is the assumptions underlying the classic twin design might 
be inaccurate. The equal environment assumption states MZ and DZ twins 
are correlated for shared environmental influences to the same extent, so 
the difference in correlation between these two types of twin pairs is solely 
due to the fact MZ and DZ twins share 100% compared to 50% of their 
segregating genes.  Studies have suggested prenatal developmental 
processes might influence the epigenetic resemblance of twins, with MZ 
twins being epigentically more similar than DZ twins owing to non-genetic 
causes (van Dongen et al., 2012).  This could potentially lead to suboptimal 
modelling of the common environment component, leading to an 
overestimation of the heritability estimates (Golan et al., 2014).  Further 
research is needed to clarify this hypothesis and its effects, especially for 
T2DM and depression. 
The “missing co-heritability” that we observed in the T2DM-
depression association could also in part be explained by the genetic effect 
of an intermediate phenotype affecting the two main traits.  Visceral 
obesity and BMI has been postulated to lie on the causal pathway between 
T2DM and depression.  It is therefore possible that obesity-related genetic 
effects might be involved in the genetic overlap between T2DM and 
depression.  For example, a gene which influences obesity will promote a 
systemic low-grade inflammation that could contribute to the development 
of both T2DM and depression.  Obesity might therefore act as a heritable 
intermediate trait conferring risk to both disorders.  “Mediated pleiotropy” 
is the term used to describe the concept when a genetic variant is linked 
to a complex phenotype because it is associated with an intermediate 
phenotype that is causally related to the complex phenotype (Solovieff, 
Cotsapas, Lee, Purcell, & Smoller, 2013).  In this thesis, I did not examine 
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the effect of obesity-polygenic scores on the T2DM-depression association. 
Future research could clarify the complex relationship between T2DM, 
depression and BMI.  I attempted to examine the potential effect of BMI 
on the genetic overlap between T2DM and depression in the deCODE and 
UK Biobank samples (chapter 6 and 7), but no conclusive conclusion could 
be drawn due to the limited power of the studies.  In addition, BMI was 
measured at the point of data collection, and no information was available 
to assess its temporal relation to the onset of T2DM and depression.  It is 
therefore possible common genetic signatures and biological pathways 
might still mediate the T2DM and depression link, despite our 
inconclusive findings.  
9.3.2 Heterogeneity of depression 
Differences in case ascertain for depression should be considered 
when interpreting our results.  For the twin studies, the sources of case 
definition differ between the studies. Hospital registries were used in both 
the Swedish and Danish twin registries whereas self-reported 
questionnaire (Beck Depression Inventory) was used in the Colombo Twin 
and Singleton Study Phase 2.  The Beck Depression Inventory was 
developed to measure the severity of depression, with participants being 
asked to rate how they have been feeling for the preceding two weeks (Beck 
et al., 1996).  It therefore captures a different timeframe (current 
presentation) to the definition used in the Swedish and Danish twin 
registries (previous/current diagnosis of depression at the time of data 
retrieval).  
For the polygenic scores analysis, the depression phenotype also 
differs across the studies.  In deCODE, it is defined by primary diagnosis 
of lifetime depression using structured diagnostic interview.  In the UK 
Biobank, it is a combination of primary diagnosis of depression using 
inpatient hospital episode data and previous visit to a General 
Practitioners/psychiatrist for stress, anxiety or depression, and at least one 
period of depression/anhedonia lasting at least two weeks using self-
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reported questionnaire. It therefore captures both current presentation 
and lifetime diagnosis of depression.  In the PGC-MDD-29 sample, four 
datasets were used in the analysis.  They all defined lifetime diagnosis of 
depression using structured diagnostic interview but different tools were 
used;  Mini Neuropsychiatric Diagnostic Interview 6.0 (Sheehan et al., 
1998) for CoFaMS, Diagnostic Interview for Genetic Studies (Nurnberger 
et al., 1994) for PsyCoLaus, Composite Interview Diagnostic Instrument 
(Wittchen, 1994) for NESDA and Mini-Mental Test (Folstein et al., 1975) 
for SHP0. The tools vary in their reliability in eliciting information to 
support this designation.  
In addition, there are variations in the diagnostic criteria for major 
depressive disorder between diagnostic classifications, namely the 
International Classification of Disease and Diagnostic and Statistical 
Manual of Mental Disorder. Criteria for major depressive disorder have 
also changed over time and different editions of the diagnostic 
classification were used to define depression in this thesis.  Epidemiology 
studies have also consistently demonstrated discrepancies between 
hospital registry data, structured diagnostic interview and self-report 
questionnaire in the diagnosis of depression. Variations in the definition 
of depression in this thesis therefore limit to a certain extent the 
generalisability of our findings.   
Depression is a difficult phenotype to define, given the overt reliance 
on subjective information for its diagnosis and the heterogeneity observed 
in both its clinical presentation and trajectory and the lack of a specific 
biomarker.  What has remained constant is that depression is a syndrome 
defined by disturbances across multiple domains i) mood, ii) anhedonia (a 
loss of interest or pleasure in daily activities), iii) changes in 
appetite/weight, iv) sleep disturbances, v) psychomotor disturbances, vi) 
fatigue, vii) feelings of guilt/worthlessness, viii) poor concentration and ix) 
suicidality.  The quality of the phenotyping is sometimes compromised in 
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genetic epidemiology in exchange for large sample sizes, in order for a 
study to have adequate power in to test specific hypothesis. 
9.3.3 Advances in GWAS  
The base dataset used to create T2DM polygenic scores was the 
summary statistics of stage 1 of DIAGRAM version 3 (Morris et al., 2012) 
and it is used in chapters 6, 7 and 8.  Two different base datasets were 
used to create depression polygenic scores, namely the summary statistics 
from PGC-MDD-1 and PGC-MDD-29  (Ripke et al., 2013). The PGC-MDD-
1 has 9240 depression cases and 9519 controls whereas PGC-MDD-29 
study has 16823 depression cases and 25632 controls (Ripke et al., 2013).  
PGC-MDD-1 was used in chapter 6 and PGC-MDD-29 was used in chapter 
7.     The reason why different base datasets were used was because the 
analysis for chapter 6 was conducted in summer 2015 and PGC-MDD-29 
was not publically available during that period.   The PGC-MDD-29 is a 
larger cohort, with more depression cases and controls. The polygenic 
scores from PGC-MDD-1 explain 0.20% of the variance in depression 
whereas the scores from PGC-MDD-29 explain 1.9%. This difference will 
have an impact on the power of the respective study in detecting the 
association between T2DM and depression polygenic scores.    
9.4 Clinical implication and future direction 
This thesis has moved the field forward by establishing a body of 
valuable knowledge into two conditions which are among the most 
important burdens on health and wellbeing globally. The clinical 
implication is hard to fully foreshadow at present, given the discrepancy 
in our findings between twin studies and GWAS.  If the genetic overlap 
between T2DM and depression as observed in twin studies is replicated in 
GWAS, the clinical implication might lie in genetic risk prediction.  It has 
the potential to identify individuals with T2DM who are at high-risk for 
depression, allowing appropriate intervention to be recommended in a 
timely manner (Wray et al., 2013).  In addition, genetic profiling may help 
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to classify treatment responders for individuals with T2DM and 
depression, allowing clinicians to treat them accordingly.  This, in turn, 
will reduce the costs of unnecessary exposure to medication for an 
individual.  At present, the amount of variance predicted by polygenic 
scores is moderate and probabilistic.  Yet, with increasingly large sample 
and international collaboration, single nucleotide polymorphisms 
associated with depression have been identified; from no significant 
finding in the PGC-MDD phase 1 study (9240 depression cases) (Ripke et 
al., 2013), to 15 loci in an analysis of self-reported depression (75607 
depression cases) (Hyde et al., 2016) and 44 loci in the latest PGC-MDD 
study (130664 depression cases) (Wray & Sullivan, 2017).  This in turn will 
improve the quality of the polygenic scores for depression. 
From a clinical intervention perspective, a useful avenue might lie 
in developing special tailored depression programme for people with 
T2DM.  For it to be effective in improving both depression and type 2 
diabetes outcomes, a multidisciplinary approach is required.  For example, 
a patient with T2DM who is at risk of depression might benefit from 
receiving cognitive behavioural therapy to recognise negative core beliefs 
and malfunction thinking styles, while occupational therapy will enable 
behavioural activation and reduce social isolation. In addition, given the 
complex interplay between weight, T2DM and depression, involvement of 
dietician for adopting healthy eating habits will be a useful addition. From 
a public health perspective, National Institute for Health and Clinical 
Excellence guideline already recommends regular depression screening for 
individual with T2DM.  This role currently mainly lies in the remit of 
practitioners working in primary care and general hospital settings.  
Raising public awareness and educating multidisciplinary team that 
patients with a chronic physical health problem such as T2DM are at a 
high risk of depression, particularly where there is functional impairment, 
is essential.  In addition, regular diabetes screening for people with 
depression will be a useful addition, addressing the discrepancy between 
physical and mental health.  
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Multiple environmental factors have been identified to influence the 
T2DM-depression association including stress, physical exercise, diet and 
lifestyle.  It is possible the interaction between genetic and environmental 
factors can influence the progression and pathogenesis of T2DM and 
depression. Gene-environment interaction is an area that needs to be 
explored in understanding the T2DM-depression association, given 
genotypes can affect an individual’s responses to the environment; 
whereas environment can differentially affect the expression of genotypes.  
In addition, research, which takes into account the epigenetic effects on 
the risk of complex traits, might hold the key to unlocking the T2DM-
depression association.  
Insulin resistance is on the causal pathway of developing T2DM and 
a meta-analysis has demonstrated a small but statistically significant 
association between insulin resistance and depression (Kan et al., 2013).  
We have postulated a theoretical model whereby the absence of feelings of 
guilt/worthlessness might be the mechanism by which a genetic propensity 
for T2DM exerts its influence on depression (chapter 8).  A similar finding 
between a genetic propensity for insulin resistance and the feelings of 
guilt/worthlessness in individuals with depression will provide evidence 
for the hypothesis, allowing further development of a biomedical model of 
for the T2DM-depression association.     
The current clinical diagnostic boundaries for depression might not 
reflect the underlying psychopathology given the extent of its phenotypic 
heterogeneity (Harald & Gordon, 2012).  There is accumulating evidence 
for developing cross-diagnostic treatment paradigms in psychiatry (Anttila 
et al., 2016).  Advances in psychiatric genetics have expanded our 
understanding of the biological underpinning of psychiatric disorders, and 
a review of the current classification of depression might inform our 
understanding of its association with T2DM.   
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9.5 Conclusion 
Studying the genetic overlap between T2DM and depression could 
help us to unravel their underlying pathophysiology, and explain the 
observed epidemiological association.  Future advances in statistical 
genetics to handle the “missing heritability” conundrum, together with 
larger samples of whole genome sequencing data, has the potential to fully 
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